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Abstract
The glycoproteins of selected microbial pathogens often include highly modified carbohydrates 
such as 2,4-diacetamidobacillosamine (diNAcBac). These glycoconjugates are involved in host 
cell interactions and may be associated with the virulence of medically-significant Gram-negative 
bacteria. In light of genetic studies demonstrating the attenuated virulence of bacterial strains in 
which modified carbohydrate biosynthesis enzymes have been knocked out, we are developing 
small molecule inhibitors of selected enzymes as tools to evaluate whether such compounds 
modulate virulence.
We performed fragment-based and high-throughput screens against an amino-sugar 
acetyltransferase enzyme, PglD, involved in biosynthesis of UDP-diNAcBac in C. jejuni. Herein 
we report optimization of the hits into potent small molecule inhibitors (IC50 <300 nM). 
Biophysical characterization shows that the best inhibitors are competitive with acetyl coenzyme 
A and an X-ray co-crystal structure reveals that binding is biased towards occupation of the 
adenine sub-pocket of the AcCoA binding site by an aromatic ring.
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Introduction
Most clinically relevant antibiotics are targeted at essential bacterial survival functions 
including replication, transcription, translation, and cell wall biosynthesis.1 This is an 
outcome of in vitro antibiotic screening and discovery, which has relied on observing cell 
death in culture in laboratory settings. The emergence of resistance against all major 
mechanisms of antibiotic action requires new paradigms for combating infectious disease. A 
potentially promising approach includes the development of agents that target bacterial 
virulence in vivo in human hosts. Such approaches may mitigate the effects of infectious 
disease, while potentially resulting in less selective pressure for resistance development.2 
Virulence factors are implicated in many bacterial processes including host-cell adhesion, 
invasion, and colonization, as well as quorum sensing and biofilm formation.2–5 In order to 
develop antivirulence agents, it is critical to identify validated pathogen-specific processes 
that cause virulence in the targeted human hosts.
Protein glycosylation is widespread in nature and regulates a variety of cellular functions 
including protein folding, cell-cell interactions, cell signaling, and the host immune 
response.6 Glycans are attached to proteins via either serine/threonine (O-linked) or the 
amide nitrogen of asparagine (N-linked). It is now recognized that selected bacteria possess 
the biosynthetic machinery for O- and/or N-glycosylation and that this modification may 
play a role in pathogenicity.7–11 N-glycosylation was first discovered in C. jejuni in 1999 
and the protein glycosylation (pgl) pathway has been characterized in detail for this 
organism (Figure 1).12,13 In C. jejuni, more than 60 proteins, including confirmed virulence 
factors, are modified with a conserved heptasaccharide.14
In a significant divergence between prokaryotes and eukaryotes, bacteria and archaea have 
specialized enzymatic processes to modify the structures of selected carbohydrates for 
incorporation into glycoconjugates. Furthermore, the discovery of unique prokaryote-
specific sugars is continuing with the pace of bacterial genome sequencing and bioanalytical 
methods development.7 In contrast to the glycosyltransferase enzymes, which assemble 
complex glycans and share common folds and mechanisms across domains of life, the 
specialized sugar-modifying enzymes are attractive targets for developing targeted 
antivirulence agents because they tend not to have mammalian homologs and because the 
associated glycoconjugates are linked with bacterial pathogenicity.15 Of particular interest is 
di-N-acetylbacillosamine (diNAcBac),16 which is derived from N-acetylglucosamine 
(GlcNAc). DiNAcBac is found, for example, at the reducing end of O-linked glycans in 
selected strains of N. gonorrhoeae and A. baumannii, and N-linked glycans in C. jejuni, 
highlighting the importance of diNAcBac biosynthesis pathways in these Gram-negative 
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pathogens.17 Intriguingly, while protein glycosylation pathways from these pathogens 
glycosylate diverse proteins with different glycans, the reducing-end sugar is 
diNAcBac.18–20 The N-linked protein glycosylation (pgl) pathway of C. jejuni and steps 
leading to diNAcBac biosynthesis are illustrated in Figure 1. The first two steps of UDP-
diNAcBac biosynthesis utilize an NAD+-dependent dehydratase (PglF) followed by a 
pyridoxal phosphate-dependent aminotransferase (PglE) to produce a UDP-4-amino-sugar, 
which is then acetylated by PglD using acetyl coenzyme A (AcCoA) as a co-substrate 
(Figure 1 inset).18 Subsequent glycan assembly onto an undecaprenyl-diphosphate carrier, is 
catalyzed by a series of glycosyl transferases. After assembly, the completed 
heptasaccharide is translocated across the inner membrane and the glycan is transferred to 
protein substrates in the bacterial periplasm by the oligosaccharyl transferase PglB.
Studies have shown that disruption of genes responsible for diNAcBac biosynthesis (pglF, 
pglE, pglD) perturb production of the native heptasaccharide glycosyl donor in C. jejuni.21 
In addition, ΔpglD and ΔpglE strains show greatly reduced colonization of the 
gastrointestinal tract of 1-day-old chicks, thereby establishing a link between protein N-
glycosylation and C. jejuni pathogenicity in host cells.22 Further insight into these effects 
came from transposon mutagenesis experiments, which identified pglF and pglE as essential 
genes for colonization. In mice, mutation of pglE impaired invasion of intestinal epithelial 
cells and colonization of the gut.23 The causative glycoconjugates underpinning these 
findings remain unknown, but several molecular associations between N-glycosylation and 
C. jejuni virulence have been defined. For example, VirB10, a structural component to the 
type IV secretion system (TFSS), needs to be glycosylated at Asn97, otherwise a 10-fold 
decrease in natural competency results.24 Recently, 16 N-linked glycoproteins were 
identified and found to be associated with C. jejuni outer membrane vesicles (OMVs) 
including the PEB3 adhesin.25 Pathogens deploy OMVs to deliver bacterial proteins into 
host cells, making this an important finding in the relationship between periplasmic 
glycoproteins and virulence.26 Protein O-glycosylation is also associated with virulence; for 
example, loss of glycosylation of PilE, a constituent of the type IV pilin in N. gonorrhoeae, 
leads to a significant decrease in epithelial cell adhesion.27
Herein we report the development of inhibitors targeting the C. jejuni PglD, a UDP-amino-
sugar acetyltransferase, which catalyzes the third step in diNAcBac biosynthesis. PglD 
represents an attractive target for inhibitor development as it is well understood from a 
structural and mechanistic perspective.28,29 Additionally, PglD is a soluble, well-expressed 
enzyme, which makes it tractable for structure/activity-driven inhibitor discovery. 
Crystallographic analysis of PglD reveals a homotrimeric structure with three equivalent 
active sites formed at the interfaces between adjacent protomers.28,29 Like many other 
bacterial UDP-amino-sugar acetyltransferases, PglD is a member of the left-handed β-helix 
family comprising two domains (Figure 2a); a N-terminal domain with a β-α-β-α-β-α 
Rossmann fold motif that binds the UDP-4-amino-sugar, and a C-terminal hexapeptide 
repeat motif that defines the left-handed β-helix that contributes to the AcCoA binding site. 
PglD has been co-crystallized in the presence of the AcCoA and UDP-4-amino-sugar 
substrates (Figure 2b).28 The structural features of PglD and related homologs differentiate 
these prokaryotic AcCoA-dependent acetyltransferases from their mammalian counterparts, 
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including for example HAT1 of the GCN5-related N-acetyltransferase (GNAT) 
superfamily.30
Currently, many questions remain as to why modified carbohydrates, such as diNAcBac, are 
incorporated into bacterial glycoconjugates. Therefore, chemical tools such as small 
molecule inhibitors that selectively block diNAcBac biosynthesis would be valuable agents 
for understanding the significance of glycan diversification in selected bacteria. In addition, 
such tools could help to validate the pgl pathway enzymes as potential antivirulence targets. 
Consequently, we have established a program to develop inhibitors of diNAcBac 
biosynthesis with a focus on the well-characterized C. jejuni pathway. This Gram-negative 
pathogen is a common cause of gastroenteritis in humans and may also result in the 
development of Guillain-Barré syndrome, an auto-immune disease in which the peripheral 
nerves are attacked resulting in damage to the myelin insulation.31,32 In recent years, C. 
jejuni has shown increased resistance towards front-line antibiotics including the macrolides 
and fluoroquinolones, which inhibit protein synthesis and DNA unwinding, respectively.33
Results
Screening
Initial hits for the development of inhibitors for PglD were identified by employing 
fragment-based screening and high-throughput molecular library approaches.34 The 
fragment-based screen was performed with a fragment set that included a selection of the 
Maybridge Ro3 chemical library as described previously.35 The primary screen involved 
differential scanning fluorimetry (DSF) analysis against PglD to identify fragments that bind 
to and stabilize the natively-folded protein. Following this, hits were confirmed by NMR 
spectroscopy (WaterLOGSY and STD) and further validated using a UV-based biochemical 
assay, which measures CoASH release following acetyl transfer to the UDP-4-amino-
sugar.36 Using this workflow, 10 compound hits with IC50 values in the 1–10 mM range and 
ligand efficiencies in the 0.29 – 0.32 range were validated. For example, compound 1 
(Figure 2), which was analyzed by X-ray in complex with PglD, binds to the central AcCoA 
binding groove occupying the pantetheine site proximal to active-site residues involved in 
amino-sugar activation and thioester attack (Figure 2c). Unfortunately, efforts to build upon 
this, and other validated fragments yielded only modest improvements in affinity. Coincident 
with these studies a high-throughput screen was performed in collaboration with the Broad 
Institute, using a Diversity-Orientated Synthesis (DOS) compound collection (83,000) and 
the NIH Molecular Libraries Probe Production Centers Network (MLPCN) library (276,000) 
of small molecules.37 Compounds were screened at 10 μM using a PglD end-point assay 
monitoring the generation of CoASH from the acetyltransferase reaction. Despite the low hit 
rate (defined as >20% inhibition) of 0.02% and 0.12% respectively, the screen led to the 
discovery of thienopyrimidinone-6-carboxylate compound 2 as a promising hit for further 
development. For direct comparison with the validated fragment hits, 2 was deconstructed to 
the core structure 3, which demonstrated a validated IC50 value of 860 μM and LE of 0.31. 
In light of these results and the tractability of the core towards synthetic manipulation at four 
points of diversification (C2, C4, C5, and C6; Scheme 1) this compound class became the 
focus of our continuing medicinal chemistry efforts.
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Preliminary structure activity studies to vary substitution at C2 generated analog 4 as the 
best inhibitor with an IC50 value of 1 μM (LE 0.33). However, although this compound 
represented a good improvement in potency, the candidate suffered from some 
disadvantages. Specifically, 4 features a planar structure with poor solubility properties and a 
metabolic liability due to the 1,3-unsubsituted indole and conjugated alkene systems. 
Furthermore, 4 and related analogs showed poor long-term stability in solution. A significant 
effort was also made to crystallize PglD with several of the thienopyrimidinone hits, 
however, this proved unsuccessful. Therefore, we performed a docking study on fragment 3 
to generate a computational model as a guide for future synthetic efforts aimed at 
eliminating the compound liabilities while improving potency.38 The thienopyrimidone-6-
carboxylate core was predicted to occupy a binding site overlapping with the panthetheine 
moiety of AcCoA, as had been previously observed in the co-crystal structure of fragment 1 
(PDB 5TYH), with similar placement of the carboxylate moiety and close agreement 
between the positions of the furan oxygen of 1 and exocyclic oxygen of 2 (compare Figure 
2c and d). Given these observations, we exploited the computational model as a guide for the 
design of the next generation of analogs, which recognized the opportunity to extend the 
molecule both at the C2 position to interact with a hydrophobic region on the β-helix, and at 
the C4 position, by transitioning to the thienopyrimidine core, to further occupy the AcCoA 
binding groove (Scheme 1).
In order to reach cytoplasmic targets in Gram-negative pathogens, compounds may enter 
cells through passive diffusion or pass through the bacterial porins to reach the periplasm 
and then reach the cytoplasm via passive or active mechanisms.39,40 With these parameters 
in mind, our overall goal was to develop potent (IC50 <500 nM) inhibitors of C. jejuni PglD 
based on the thienopyrimidine-6-carboxylate core with good ligand efficiency (LE >0.30) 
together with balanced physicochemical properties including cLogP values between 2 – 4.41
Chemistry
We developed modular synthetic routes to provide access to the target thienopyrimidine 
carboxylic acids with readily-modifiable substitution at the C2 and C4 positions (Schemes 2 
and 3).
For modification at the C2-position (Scheme 2, Route I), the synthesis was initiated by 
condensation of commercially available thiophene, 5, with nitriles bearing the desired R2 
substituent, under strongly acidic conditions. In most cases, the thienopyrimidone products 
of general structure 6, proved highly insoluble, and therefore chromatography and NMR 
characterization was carried out after the subsequent step. In cases where nitriles with the 
appropriate R2 moiety were inaccessible, an alternative approach (Route II) was employed. 
This route is somewhat longer and includes a Michaelis-Arbuzov reaction with triethyl 
phosphite and analog 6 (Core structure: R2 = -CH2Cl) to furnish phosphonate 8. Subsequent 
Horner-Wadsworth-Emmons (HWE) olefination and hydrogenation generated 
thienopyrimidinones of general structure 9 with a variety of phenylethyl substituents at the 
C2-position.
Installation of a substituent at the C4-position of thienopyrimidines is typically 
accomplished by transforming the C4 oxygen of the thienopyrimidone into chloride or 
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bromide, with POCl3 and PBr3 respectively, followed by a SNAr reaction, both performed at 
high temperatures. To avoid use of these harsh conditions and strong lachrymators, we 
instead employed a one-step, room temperature reaction modified from chemistry developed 
by researchers at Wyeth.42 Utilization of a sufficiently strong base, such as 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), in excess solubilized the thienopyrimidinones in 
acetonitrile and replacing the toxic and expensive BOP reagent for the readily available 
PyBOP, allowed for robust formation of the desired pyrimidines of general structure 10 in 
good yields (40–90%). These thienopyrimidines could be isolated by column 
chromatography in excellent purity (>95% homogeneity as determined by LC-MS). The 
final saponification of thioenopyrimidine esters represented by 7 and 10 was achieved in a 
THF/MeOH/H2O mixture containing NaOH; occasionally mild heating was required to 
achieve complete conversion. The final inhibitors with core scaffold 11 were isolated by 
trituration as easy to handle solids.
A related thienopyrimidine isomer with general structure 16, was accessed as described in 
Scheme 3. In this case, the thiophene starting material 14 is not commercially available but 
could be readily prepared by the esterification of dicarboxylic acid 12 followed by nitration 
and hydrogenation. Condensation with nitriles provided thienopyrimidinones of general 
structure 15, which differ from the scaffold 11 series in the relative location of the sulfur 
atom and the absence of a methyl group on the thiophene ring. Installation of substituents at 
C4 and saponification were performed as described previously, to provide inhibitors with 
core scaffold 16.
Initial SAR analysis
All target thienopyrimidine carboxylic acids 11 and 16 (Figure 3) were assayed for 
inhibition of recombinantly-expressed and purified C. jejuni NCTC 11168 PglD 
acetyltransferase.18 The continuous assay monitors the release of CoASH using 5,5′-
dithiobis-(2-nitrobenzoic acid,36 and was carried out at 300 μM AcCoA (Km of 295 μM), 
and 500 μM UDP-4-amino-sugar (Km of 274 μM). IC50 values of selected compounds are 
summarized in Table 1. The AcCoA concentration was aligned with reported physiologic 
concentrations in typical Gram-negative bacteria.43
Our initial strategy was to explore the C2- and C4-substituents individually and then 
combine the optimal structural components from each series to capture advantageous 
synergistic binding effects. We observed that short aliphatic chains and saturated carbocycles 
at C2 (with R4 = Me) provided weak inhibitors with IC50 values in the 10 μM to 1 mM range 
(data not shown). Based on these studies we selected an unsubstituted phenylethyl moiety 
(Figure 3, substituent d) as a favorable C2-substituent in terms of potency gain versus added 
mass (e.g. 17, IC50 = 2.2 μM, LE 0.35, Table 1). However, when we explored C4-
substituents (with R2 = H), these analogs proved to be poor inhibitors (IC50 > 500 μM, data 
not shown) and SAR trends could not be well defined from the data. Accordingly, we elected 
to directly prepare disubstituted analogs, with R2 = phenylethyl (d), and iteratively build up 
the R4 substituent in terms of length, sterics and heteroatom substitution (e.g. inhibitors 18–
35; shorter and smaller substituents omitted for brevity). In general, only modest gains in 
potency could be achieved, and all the gains were at the cost of poorer ligand efficiencies. 
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Ultimately, we observed that a phenylethyl moiety was also well tolerated at the C4-position 
of the thienopyrimidine core (20, R2 = R4 = phenylethyl, IC50 = 1.4 μM).
In order to gain a better understanding of the binding behaviour of the inhibitors, we 
examined the results of the phenyl scan on the R4 substituent, which positioned moieties 
with different characteristics (sterics, polarity and hydrogen-bonding capabilities) ortho, 
meta or para on the aryl ring (inhibitors 21–35). However, while we had predicted that these 
substitutions would either complement or clash with the protein surface resulting in a 
measurable difference in IC50 values, we instead observed a “flat” SAR with inhibitors 
exhibiting IC50 values around 0.5 μM (e.g. 21–35). Indeed, only substitution with an 
acetamido group (33–35) elicited clear variances, with the ortho substitution being the most 
disfavored (35, IC50 = 9.0 μM). A potential explanation for the flat SAR could be that if the 
aryl group occupies the AcCoA binding groove then one edge would face the protein surface 
and the other would be solvent exposed, thus precluding any interaction between the 
moieties on the R4-aryl ring and the protein surface. This hypothesis was tested by preparing 
analogs bearing two moieties on the aryl ring (inhibitors 36–38), however, potency remained 
at 0.5 μM.
In light of these data, we developed two hypotheses. One potential hypothesis was that the 
compounds might have a different mode of action other than competitive inhibition with the 
AcCoA substrate. We explored this by applying several biochemical and biophysical 
approaches, which are presented in the next section (vide infra). The second possibility was 
that the inhibitor binding mode differed significantly from that predicted by the 
computational model; for example, either the ligands bind in a different location on the PglD 
protein surface or the enzyme itself undergoes a significant conformational change. We also 
noted that the C2, C4-disubstituted inhibitors were inherently quite symmetrical, with a 
pseudo C2 axis of rotation in the plane of the thienopyrimidine core (Figure 4a). This feature 
might explain the flat SAR observed for the phenyl scan of the R4-substituent since the 
effect of any moiety on the aryl group could potentially be masked if the ligand flipped 180° 
and positioned the R2-substituent in the AcCoA binding groove instead. To test this 
hypothesis, we synthesized inhibitors 49 and 50, which included the quasi-regioisomeric 
thienopyrimidine core 16 and, if the binding orientation remains true, should position the 
sulfur atom towards the protein surface. Indeed, these inhibitors had similar potency to their 
parent analogs (compare 49 IC50 = 3.9 μM vs. 17 IC50 = 2.2 μM, and 50 IC50 = 1.4 μM vs. 
41 IC50 = 1.1 μM), suggesting the thienopyrimidine carboxylic core can bind in either of 
two orientations into the AcCoA binding groove. To further validate this hypothesis, we 
developed inhibitors that would be locked in a fixed conformation by introducing rigidifying 
elements in the alkyl linkers between the thienopyrimidine core and substituent aryl groups. 
Synthetically it was straightforward to add a methyl group on the second carbon of the R2-
substituent and a methoxy group on the second carbon of the R4-substituent; the prerequisite 
starting materials were commercially available as both stereoisomers and could be easily 
transformed into the corresponding nitrile or amine for the modular syntheses (Figure 4b). 
With the four rigidified analogs we would expect to see data consistent with a matched/
mismatched phenomenon; either substituent should have an enantiomer that complements 
the protein surface better than the other and when combined these effects should result in 
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one poor inhibitor, two moderate ones and a single preferred analog. Indeed, this was 
observed with compounds 51–54 (Figure 4b), albeit in a modest IC50 range. These combined 
results strongly suggested that the inhibitors were capable of binding to the PglD active site 
with either the R2-, or R4-substituent in the AcCoA groove.
Overall, the SAR data (Figure 4) shows that while binding may be somewhat promiscuous, 
the R2-substituent was far more important for binding potency. This experimental 
observation was therefore inconsistent with our initial computational model, which had 
oriented this substituent over the β-helix (and quite solvent exposed) and placed the R4-
substituent in the AcCoA groove. These findings prompted us to investigate the binding 
mode in more detail, to provide a foundation for the next synthetic and biochemical efforts.
Biophysical characterization and inhibitor optimization
With the knowledge gained from SAR studies up to this point, we generated a potent C. 
jejuni PglD inhibitor, 55 (Figure 5), with an IC50 of 270 nM; however, this was at the cost of 
decreased ligand efficiency (0.26) and a high cLogP (5.12). In order to further optimize the 
potency and physicochemical properties of these compounds, we needed to better 
characterize their binding characteristics. Towards this end, we employed several 
complementary approaches including the PglD inhibition assay with varying substrate 
concentrations, DSF analysis, dynamic light scattering (DLS) and X-ray crystallography.
We had first initiated inhibitor development based on modeling studies, which suggested that 
the thienopyrimidine carboxylate core competed with the AcCoA substrate for binding to 
the PglD active site. To test this experimentally, we monitored inhibition in the presence of 
varying concentrations of the two substrates. We observed that significantly higher 
concentrations of the UDP-4-amino-sugar substrate had no measurable effect on the 
inhibition by a representative analog of 11 (compound 37, supporting information Table S2). 
In contrast, a 2-, and 5-fold increase in AcCoA substrate concentration resulted in measured 
IC50 values of 0.63 μM and 1.4 μM, respectively. These values represent a 2- and 4-fold 
decrease in potency and strongly suggest that the thienopyrimidine carboxylate inhibitors 
compete with AcCoA for binding to the PglD active site.
All of the data thus far has been based on the enzymatic inhibition assay and, despite the 
judicious use of detergent and BSA to prevent aggregation phenomena,44 may be prone to 
artefacts that obscure binding trends. We therefore employed DSF as a qualitative secondary 
assay to assess binding of inhibitors to the C. jejuni PglD. DSF employs a fluorescent dye, 
Sypro Orange, to report on the thermal denaturation of a protein or protein/ligand 
complex.45 Potent inhibitors bind to their target enzyme more strongly that weak ones, 
resulting in a more stable protein/ligand complex and higher measured melting temperature 
(Tm). Therefore, the thermal stabilization (ΔTm) of PglD can be used to provide an indirect 
measure of the relative binding affinity of the related family of compounds. We selected a 
subset of inhibitors with a range of IC50 values and structural characteristics to analyze by 
DSF and plotted the ΔTm vs IC50 values (Figure 6). The graph shows a positive correlation 
(R2 = 0.72) between inhibition potency and thermal stabilization over a range of IC50 values 
indicating that the compounds stabilize the native PglD homotrimer and that the more potent 
compounds, based on IC50 values, indeed stabilize PglD more effectively.
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Next, we analyzed the enzyme quaternary structure in solution by dynamic light scattering 
(DLS) and found the calculated hydrodynamic radius of apo PglD to be ~34 Å, consistent 
with the crystal structures of trimeric PglD (supporting information Figure S1). In the 
presence of 10-fold excess of inhibitor 55, the measured radius was marginally larger, ~36 
Å, yet still consistent with the known trimeric structure. We also noted that the 
polydispersity index (PDI) of the PglD/55 complex (24 % PDI) was lower than apo PglD 
(31% PDI), providing strong support that the inhibitor does not destabilize quaternary 
structure and indeed binds to the homotrimeric enzyme.
Throughout these efforts we also continued to pursue crystallization attempts to gain 
structural insight on representative thienopyrimidine analogs. X-ray analysis of the C. jejuni 
NCTC 11168 PglD enzyme has been successfully carried out in our group and others.28,29 
Typically, the reported precipitant solutions were either high ionic strength (1.9 M 
ammonium sulfate) or contained acidic buffer components that were frequently observed to 
bind in the enzyme active site (sulfate, phosphate, citrate).28,29 Despite numerous attempts, 
application of previously published protocols did not yield co-crystal structures with the 
current thienopyrimidine-6-carboxylate inhibitors and thus we screened for new conditions 
that would be more compatible with the binding of small organic molecules. Ultimately, a 
crystallization hit with PEG-3350 was successfully optimized to reliably produce high 
quality crystals. The crystals develop as hollow, hexagonal rods that fill in from one end as 
they mature; producing either “vase-like” or solid crystals (Figure S3). The diffraction 
quality did not appear to differ between a solid or hollow end of such crystals. The crystals 
were tolerant of DMSO in concentrations up to 10%, but tended to be rather fragile and 
could break upon looping. Therefore, we employed an “in-drop soaking” protocol, in which 
a solution of the inhibitor is directly added to the drop containing the crystals.
Using these crystallization conditions, we were able to obtain high-quality diffraction data 
and successfully solve the co-crystal structure of the PglD/17 complex (Figure 7 and S4). 
From the structure, two significant observations were immediately evident. Firstly, as 
anticipated from the SAR studies, the thienopyrimidine core was flipped 180° compared to 
the computational model developed with the core fragment, with the R2-subsituent binding 
in the AcCoA groove (Figure 7, panel b). This position of the thienopyrimidine core directs 
the R4-subsituent away from the AcCoA groove and into solvent where it makes no 
significant interactions with the PglD protein surface (Figure S5, LigPlot46). This 
observation is consistent with our SAR findings that R4-subsituent makes small 
contributions to inhibitor potency at the expense of ligand efficiency (Table 1). Secondly, the 
most surprising observation was that the ligand was bound 3.9 Å further along the AcCoA 
groove, relocating the carboxylate distal to the acetyltransferase active site where the 
AcCoA thioester is normally accommodated. This observation was rather unexpected as we 
assumed that the Asn118, H134 and S136 residues would be preferred hydrogen-bonding 
partners for the inhibitor carboxylic acid moiety. Furthermore, this displacement precludes a 
T-shaped π-stacking between the side chain of Phe152 and the thienopyrimidine core; 
instead the binding mode positions Phe152 at an offset angle over the inhibitor carboxylate 
(Figure S4). To compensate, inhibitor 17 makes several other key interactions with the PglD 
surface; the carboxylic acid moiety is positioned at a favorable distance and orientation to 
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form hydrogen bonds with the Ser136 side chain and the backbone amide NH of Ile155. 
Similarly, the thienopyrimidine N1 atom is well placed to interact with Gly173. From the 
structure it appears that a definitive interaction may be the placement of the R2 phenyl ring 
within the AcCoA adenine binding sub-pocket, displacing solvent waters from a relatively 
hydrophobic protein cavity. The ligand binding mode is also internally favorable (low 
torsion) as the bound conformation adopts an anti-periplanar angle of approximately 160° 
along the benzylidene bond between the thienopyridimine core and R2 phenyl ring (Figure 
7c).
Armed with this new structural information we set out to further optimize the inhibitor 
series. First we investigated the possibility of simultaneously placing the R2 phenyl ring in 
the adenine sub-pocket and the carboxylate in the active site hot spot by increasing the linker 
length between the inhibitor core and R2-substituent. This did not prove successful as 
analogs 39 and 40 (with a 3- and 4-carbon linker respectively) demonstrated lower in vitro 
potency; presumably due to internal strain of unfavorable torsion angles of the alkyl linker. 
Secondly we noted that although the R2 phenyl group fits well in the adenine sub-pocket, it 
does not fully occupy the volume of the [6,5]-fused ring cavity and there was unoccupied 
space at the meta position relative to the linker (Figure 7c). We explored several moieties at 
this position (41 –OMe, 42 –F, 46 –Cl and 47 –CF3, Table 1), but only gained a minor 
improvement in potency with compound 41 (IC50 = 1.1 μM). Finally upon closer inspection 
of the adenine sub-pocket we speculated that if the aromatic carbon at a position ortho to the 
linker is replaced by a nitrogen and protonated, it would be well-oriented to form a hydrogen 
bond with the backbone oxygen of Gly173, as it does with the exocyclic amine of the 
adenine of the AcCoA substrate (PDB ID 3BSY).28 While the resultant pyridine nitrogen is 
only weakly basic, it could potentially be protonated in the microenvironment of the enzyme 
and lead to an order of magnitude improvement in potency. For example, the pyridine 
derivative risedronic acid is a ~300-fold more potent inhibitor of the human farnesyl 
pyrophosphate synthase than the corresponding phenyl analog.47 Although not as 
significant, the 4.8-fold fold enhancement we observed between inhibitor 43 (IC50 = 0.46 
μM) and 17 (IC50 = 2.2 μM) is very interesting considering the minor nature of the structural 
change. Although 43 is not the most potent inhibitor, it exhibits the best ligand efficiency, 
0.39, and has a cLogP of 2.94, within the −0.5 – 3 range that is thought to be ideal to reach 
cytoplasmic targets of Gram-negative bacteria; with these characteristics 43 represents our 
best candidate to date with balanced physicochemical properties.
Discussion and Conclusions
In the development of inhibitors of the C. jejuni UDP-4-amino-sugar acetyltransferase, 
PglD, we initially screened both fragment-based and HTS libraries. These studies led to the 
identification of a thienopyrimidine-6-carboxylate core as a promising hit. Over the course 
of the SAR studies we found substitution at the C2-position of the core to be most impactful 
and that the binding mode appeared to be poorly predicted in silico. By combining data from 
substrate competition assays, DSF, and DLS we confirmed that the inhibitors bind 
exclusively to the AcCoA binding groove of the active site without disrupting the homo-
trimeric structure of PglD.
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Critically, crystallographic analysis reveals a 180° flip of the thienopyrimidine core to place 
the R2-substituent in the AcCoA groove, as was anticipated from the SAR data. However, in 
contrast to previously characterized small fragments, we observed a 3.9 Å displacement of 
the inhibitor further along the AcCoA groove away from the known thioester binding site. 
Notably, in this new binding mode, the inhibitor makes several hydrogen-bonding 
interactions that compensate for the ones that would have been formed with the key catalytic 
residues (Asn118 & His134), but also precludes a stabilizing T-shaped π-interaction 
between the thienopyrimidine core and Phe152. Ultimately, it appears that placement of the 
R2-phenyl into the adenine sub-pocket of AcCoA binding site may be the main driving force 
of ligand binding and indeed further optimization of this interaction resulted in to our most 
promising lead. Specifically, inhibitor 43 (IC50 = 0.46 μM) shows an excellent ligand 
efficiency of 0.39 and a favorable clogP of 2.94. To the best of our knowledge this is the first 
competitive inhibitor with an IC50 value < 1 μM for a bacterial amino-sugar-modifying 
enzyme. A selection of inhibitors from the series presented herein was also tested against the 
structurally homologous amino-sugar acetyltransferase from N. gonorrhoeae (PglC in that 
O-linked glycosylation pathway) and no significant inhibition was observed even at 100 μM. 
This observation was not surprising considering the significant differences between the 
AcCoA binding sites of the two enzymes.48
With respect to biological analysis, the in vivo analysis of inhibitors that target bacterial 
virulence factors requires more complex experimental approaches than the simple estimation 
of minimal inhibitory concentrations (MICs) used in assessing bacterial viability with 
antibiotics that are targeted at cell survival processes. We are therefore pursuing multiple 
strategies to investigate in vivo efficacy both directly in C. jejuni, by assessing the impact of 
the inhibitors on glycoprotein biosynthesis, and in cell culture models of mammalian gut 
endothelia assessing C. jejuni adhesion and invasion. Currently, despite robust in vitro 
activity, we do not observe a reduction in glycosylation of periplasmic and cell surface 
proteins upon treatment of C. jejuni with the current inhibitors. This observation may be the 
result of insufficient inhibition potency against the target and/or may result from limited 
cellular uptake or efflux. In this context, C. jejuni features both a formidable cell wall 
including inner and outer cell membranes flanking a peptidoglycan barrier together with a 
dense external glycocalyx, as well as an active CmeABC efflux pump system to guard 
against external chemical agents.49 With respect to potency, the X-ray analysis of PglD with 
compound 17 provides an excellent foundation for further structure-guided optimization of 
the thienopyrimidine core. Concerning cellular uptake and efflux, which are common 
impediments to antibiotic activity in Gram-negative pathogens, the presented 
thienopyrimidine core also offers considerable opportunities. In particular, we are exploring 
several strategies including bioisosteric replacement of the carboxylate moiety and 
development of pro-drug analogs in consideration of the fact that the negative charge of the 
carboxylic acid moiety might acting as an impediment for compound uptake into the 
cytoplasm, which is the site of PglD activity. Additionally, the C4-substituent of the 
thienopyrimidine series represents a valuable handle for modulating the cLogP of the 
inhibitor, since we have demonstrated that substitution at this site can be varied without 
adversely perturbing PglD inhibition. As elegantly demonstrated in a recent study of another 
Gram-negative pathogen, researchers have shown that fine-tuning the physical properties of 
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inhibitors, in this case to mimic the zwitterionic charge distribution of amino acids, allowed 
novel carbapenem analogs to pass through the OccD1 membrane porin of P. aeruginosa.50 
Thus the thienopyrimidine compounds in this report are amenable to further such 
optimizations and current efforts are focused on overcoming the C. jejuni defenses to 
validate PglD as a potential antivirulence target in the biological context of infection.
Overall the studies presented herein support further development of small molecule 
inhibitors as tools for investigating of the role diNAcBac in bacterial glycosylation and how 
it relates to pathogenicity. Promising candidates targeting important virulence factors have 
already been documented, including agents inhibiting pilus assembly in uropathogenic E. 
coli51 and bacterial motility by inhibiting disulfide formation of periplasmic proteins.52 
Progress has also been made towards modulators of quorum sensing.53 Closely related to the 
work in this paper, the Sulea and Logan research groups have reported an inhibitor that 
targets the pseudaminic acid biosynthetic pathway found in H. pylori and C. jejuni.54 The 
“sialic-acid like” nonulosonate sugar product is required for the glycosylation of structural 
flagellin proteins and exposure to inhibitors attenuated flagellin production at concentrations 
of ≥100 μM. The flagella are required for persistent infections of H. pylori and this work 
demonstrates the link between bacterial glycosylation and pathogenicity using chemical 
tools (as opposed to genetic modification). The most advanced antivirulence work has been 
accomplished with N-phenyl-4-(3-phenylthioureido)benzenesulfonamide, 56 (LED209), a 
prodrug agent that covalently inhibits QseC, a receptor involved in signaling between many 
Gram-negative pathogens and the infected host.55 Treatment with 56 in a mouse infection 
model showed prophylactic efficacy against S. typhimurium and provided protection against 
F. tularensis both pre- and post-infection. Furthermore, 56 was not toxic at therapeutic doses 
and did not affect pathogen growth in vitro. These promising in vivo results are compelling 
evidence that killing is not necessarily required for treatment of bacterial infection and 
alternate therapeutic intervention strategies are worth exploring.
In conclusion, herein we disclose the hit-to-lead development of a new series of 
thienopyrimidine-6-carboxylate inhibitors of the C. jejuni PglD UDP-amino-sugar 
acetyltransferase enzyme, which, upon further optimization could represent valuable 
chemical tools for unraveling the intricate biological role(s) of highly modified sugars in 
bacteria and potentially may lead to new agents with targeted antivirulence activity.
Experimental section
General Procedures for Characterization of Compounds
All intermediate compounds were purified by normal phase flash column chromatography 
on silica gel using a CombiFlash instrument. The homogeneity of all final compounds was 
confirmed to ≥95% by analytical reverse-phase LC-MS using an Agilent Series 1100 HPLC 
instrument equipped with a YMC AQ12S03-1003WT C18 column and a Finnigan LCQ 
Deca electrospray ionization mass spectrometer, using a gradient of 5–95% in 20 min of 
acetonitrile in water with 0.1% TFA. Each final compound was fully characterized by 1H 
and 13C NMR and HRMS. Chemical shifts (δ) are reported in ppm relative to the internal 
deuterated solvent (1H, 13C), unless indicated otherwise. The high-resolution MS spectra of 
final products were recorded using direct analysis in real time (DART) ionization on a 
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Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer (FT-ICR-MS).
General procedure for the formation of thienopyrimidinones – Parent structure 6
A pressure vessel washed charged with aminothiophene (1 equivalent) and nitrile (1–1.2 
equivalents) and 4M HCl in dioxane was added via syringe. The pressure vessel was tightly 
sealed with a Teflon screw cap stopper and the reaction was stirred at 80°C until the reaction 
was complete, as judged by TLC. The reaction mixture was cooled to room temperature, 
transferred to an Erlenmeyer flask in an ice-bath with a minimum volume of methanol and 
diluted with water (10-fold of solvent volume). The pH was brought to ~8 with ammonium 
hydroxide solution (25%) resulting in precipitate formation. The mixture was held on ice for 
15–60 min and then filtered over filter paper; washing with distilled water. The residue was 
dried under vacuum to afford the desired thienopyrimidine in sufficient purity for the 
subsequent step. Due to the poor solubility of these compounds, full characterization was 
performed after the next synthetic step and purification.
Ethyl 2-((diethoxyphosphoryl)methyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-
carboxylate (8)
A 100 mL RBF was charged with ethyl 2-(chloromethyl)-5-methyl-4-oxo-3,4-
dihydrothieno[2,3-d]pyrimidine-6-carboxylate (900 mg, 3.13 mmol) (6) and 
triethylphosphite (10.4 g, 10.8 mL, 62.8 mmol) was added via syringe and the reaction was 
heated at 145 °C for 2 h. The reaction mixture was cooled down, diluted with 100 mL 
diethyl ether and stirred for 1 h on ice. The suspension was filtered, washed with copious 
amounts of ether and petroleum ether. The obtained residue was dried on high vacuum to 
furnish the desired the product as a fine, free-flowing white powder, 994 mg (82%). 1H 
NMR (500 MHz, DMSO) δ 12.62 (s, NH), 4.28 (q, J = 7.1 Hz, 2H), 4.10 – 3.99 (m, 4H), 
3.37 (d, J = 22.2 Hz, 2H), 2.79 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 7.0 Hz, 6H). 13C 
NMR (126 MHz, DMSO) δ 166.99 (d, J = 3.0 Hz), 162.98, 159.97, 154.77 (d, J = 8.6 Hz), 
144.46, 122.93, 122.17, 63.42 (d, J = 6.3 Hz), 62.28, 33.99 (d, J = 131.2 Hz), 17.30 (d, J = 
6.0 Hz), 15.95, 15.29. 31P NMR (121 MHz, DMSO) δ 21.87. MS (ESI): calcd. 389.09; 
found 389.07 [M+H]+.
General procedure for the Horner-Wadsworth-Emmons reactions
To an ice-cooled solution of phosphonate 8 (1 equivalent) and aldehyde (3 equivalents) in 
anhydrous THF was added sodium hydride (60% suspension in mineral oil, 3 equivalents) in 
small portions. The reaction was stirred at RT until complete consumption of starting 
material, as determined by TLC. The crude product was poured into ice-water (5 times the 
reaction solvent volume), filtered and washed with water. The filter-cake was washed with 
ice-cold ethanol, diethyl ether and pentanes. The residue was dried on high vacuum to 
furnish the desired product in sufficient purity for subsequent reactions.
General procedure for the hydrogenation reactions
A round bottom flask was charged with the alkene product from the HWE reaction, 
suspended in MeOH/THF/NH4OH 10:2:1 and purged with nitrogen. Pearlman’s catalyst was 
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added (20% Pd(OH)2/C, 0.5 equivalents, CAS 12135-22-7), and the reaction mixture was 
purged with H2 gas and equipped with an H2-filled balloon. The reaction was stirred at 60°C 
until complete consumption of starting material, as determined by TLC, replenishing the H2 
balloon as needed. The reaction mixture was purged with nitrogen and filtered through a 
plug of Celite, rinsing with EtOAc. The filtrate was concentrated in vacuo and the obtained 
material was used without further purification.
General procedure for the formation of ester precursors (10)
To a solution of or thienopyrimidinone (1 equivalent) and (benzotriazol-1-yloxy)-
tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.3 equivalents) in anhydrous 
acetonitrile was added 1,8-diazabicyclo[5.4.0]undec-7-ene (1.5 equivalents, 3 equivalents in 
case of amine-HCl salts) via syringe. The mixture was stirred at RT for 5 min, after which 
the nucleophile (1.5 equivalents) was added and the reaction stirred at RT until complete 
consumption of starting material, as determined by TLC. The solvent was removed in vacuo 
and the crude residue was purified by column chromatography on silica gel using a gradient 
of EtOAc in 1:1 Hex/CH2Cl2. Note: Substituent b was introduced as a mono-Boc-protected 
diamine; the Boc protecting group was expediently removed by treating the compound with 
4 M HCl in 1,4-dioxane followed by precipitation with cold diethyl ether and filtration.
Ethyl 5-methyl-4-(methylamino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 10(d,a)
Isolated 80 mg (77% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.19 (m, 
4H), 7.17 – 7.12 (m, 1H), 7.09 (m, NH), 4.28 (q, J = 7.1 Hz, 2H), 3.09 – 3.04 (m, 2H), 3.02 
– 2.97 (m, 5H), 2.86 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
168.26, 167.97, 163.50, 159.84, 142.72, 141.08, 129.47, 129.39, 126.92, 120.08, 115.95, 
62.16, 41.31, 34.42, 29.27, 16.74, 15.34. MS (ESI): calcd. 356.14; found 356.27 [M+H]+.
Ethyl 4-((2-aminoethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 
10(d,b)
Isolated 70 mg (92% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.00 (br. s., 
NH2), 7.48 (m, NH), 7.29 – 7.24 (m, 4H), 7.19 – 7.14 (m, 1H), 4.30 (q, J = 7.1 Hz, 2H), 3.81 
(q, J = 5.6 Hz, 2H), 3.12 – 3.03 (m, 6H), 2.95 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H).13C NMR (75 
MHz, DMSO) δ 165.02, 162.48, 159.04, 141.38, 140.89, 129.04, 128.98, 126.75, 121.53, 
116.43, 62.15, 38.60, 38.41, 33.27, 16.21, 14.79. MS (ESI): calcd. 385.170; found 385.20 
[M+H]+.
Ethyl 4-(benzylamino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylate 10(d,c)
Isolated 80 mg (79% yield) as an off-white solid. 1H NMR (500 MHz, DMSO) δ 7.70 (m, 
NH2), 7.40 (d, J = 7.7 Hz, 2H), 7.29 (t, J = 7.6 Hz, 2H), 7.23 – 7.15 (m, 3H), 7.09 (m, 3H), 
4.75 (d, J = 5.8 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.93 (m, 7H), 1.28 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, DMSO) δ 168.26, 168.09, 163.46, 159.24, 142.59, 141.04, 140.88, 129.38, 
129.33, 128.52, 127.77, 126.85, 120.39, 115.86, 62.19, 45.07, 41.25, 34.27, 16.88, 15.31. 
MS (ESI): calcd. 432.17; found 432.33 [M+H]+.
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Ethyl 5-methyl-2-phenethyl-4-(phenethylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(d,d)
Isolated 106 mg (91% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.32 – 
7.16 (m, 8H & NH), 7.16 – 7.07 (m, 2H), 4.26 (q, J = 7.0 Hz, 2H), 3.72 (dd, J = 14.0, 6.3 
Hz, 2H), 3.13 – 3.05 (m, 2H), 3.05 – 2.96 (m, 2H), 2.94 – 2.86 (m, 2H), 2.79 (s, 3H), 1.27 (t, 
J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.22, 168.19, 163.44, 159.23, 142.67, 
140.85, 140.67, 129.82, 129.55, 129.40, 129.37, 127.29, 126.93, 120.27, 115.77, 62.14, 
43.49, 41.29, 35.77, 34.47, 16.60, 15.30. MS (ESI): calcd. 446.19; found 446.40 [M+H]+.
Ethyl 4-((4-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,g)
Isolated 172 mg (83% yield) as an off-white solid. 1H NMR (500 MHz, DMSO) δ 7.26 – 
7.20 (m, 4H), 7.18 – 7.09 (m, 3H & NH), 6.86 (d, J = 8.6 Hz, 2H), 4.28 (q, J = 7.1 Hz, 2H), 
3.71 – 3.66 (m, 5H), 3.12 – 3.07 (m, 2H), 3.03 – 2.99 (m, 2H), 2.86 – 2.80 (m, 5H), 1.28 (t, J 
= 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.07, 163.30, 158.99, 158.70, 142.08, 
138.32, 130.92, 130.03, 128.70, 128.55, 126.07, 121.47, 115.33, 114.46, 61.45, 55.53, 
42.47, 41.16, 34.55, 34.46, 15.70, 14.58. MS (ESI): calcd. 476.20; found 476.40 [M+H]+.
Ethyl 4-((3-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,h)
Isolated 182 mg (87% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 
7.19 (m, 6H), 7.17 – 7.11 (m, 1H 7 NH), 6.82 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.73 (m, 
2H), 3.69 (s, 3H), 3.10 (m, 2H), 3.01 (m, 2H), 2.91 – 2.86 (m, 2H), 2.82 (s, 3H), 1.28 (t, J = 
7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.05, 163.28, 160.23, 158.96, 142.08, 140.67, 
138.35, 130.10, 128.70, 128.56, 126.08, 121.47, 121.36, 115.34, 114.92, 112.13, 61.45, 
55.39, 42.27, 41.18, 35.41, 34.56, 15.66, 14.58. MS (ESI): calcd. 476.20; found 476.47 [M
+H]+.
Ethyl 4-((2-methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,i)
Isolated 198 mg (95% yield) as a beige solid. 1H NMR (500 MHz, DMSO) δ 7.25 – 7.11 
(m, 7H), 7.08 (m, NH), 6.95 (d, J = 7.6 Hz, 1H), 6.86 (td, J = 7.4, 1.0 Hz, 1H), 4.28 (q, J = 
7.1 Hz, 2H), 3.74 (s, 3H), 3.73 – 3.68 (m, 2H), 3.09 (m, 2H), 3.00 (m, 2H), 2.92 (t, J = 7.3 
Hz, 2H), 2.81 (s, 3H), 1.30 – 1.26 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 168.04, 163.38, 
159.12, 157.72, 142.17, 138.59, 130.92, 128.72, 128.54, 128.39, 127.51, 126.04, 121.11, 
115.32, 110.79, 61.40, 55.61, 41.84, 41.19, 34.53, 29.65, 15.62, 14.59. MS (ESI): calcd. 
476.20; found 476.27 [M+H]+.
Ethyl 4-((4-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,j)
Isolated 183 mg (90% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.32 – 
7.23 (m, 4H), 7.21 – 7.12 (m, 3H), 7.02 (m, 2H), 5.61 (t, J = 5.5 Hz, NH), 4.34 (q, J = 7.1 
Hz, 2H), 3.85 (dd, J = 12.5, 6.8 Hz, 2H), 3.22 – 3.14 (m, 4H), 2.94 (m, 2H), 2.71 (s, 3H), 
1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.02, 163.25, 161.95 (d, J = 245.0 
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Hz), 158.92, 142.03, 138.10, 134.79 (d, J = 3.3 Hz), 130.55, 130.44, 128.67, 128.57, 126.09, 
121.68, 115.82 (d, J = 21.2 Hz), 115.30, 61.49, 42.44, 41.14, 34.63, 34.54, 15.71, 14.57. MS 
(ESI): calcd. 464.18; found 464.47 [M+H]+.
Ethyl 4-((3-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,k)
Isolated 168 mg (83% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 
7.23 (m, 5H), 7.18 (m, 1H), 7.05 – 6.89 (m, 3H), 5.63 (t, J = 5.4 Hz, NH), 4.34 (q, J = 7.1 
Hz, 2H), 3.87 (dd, J = 12.5, 6.8 Hz, 2H), 3.23 – 3.15 (m, 4H), 2.96 (m, 2H), 2.72 (s, 3H), 
1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.01, 163.27 (d, J = 246.3 Hz), 
163.23, 158.88, 142.02, 141.77 (d, J = 7.1 Hz), 138.14, 130.49 (d, J = 8.3 Hz), 128.68, 
128.57, 126.09, 124.78, 124.75, 121.68, 115.90 (d, J = 20.9 Hz), 115.31, 113.88 (d, J = 21.0 
Hz), 61.48, 42.17, 41.16, 35.21, 34.56, 15.69, 14.57. MS (ESI): calcd. 464.18; found 464.47 
[M+H]+.
Ethyl 4-((2-fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,l)
Isolated 170 mg (84% yield) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ 7.32 – 
7.02 (m, 9H), 5.69 (t, J = 5.4 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.89 (dd, J = 12.4, 6.6 Hz, 
2H), 3.23 – 3.12 (m, 4H), 3.04 (m, 2H), 2.76 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 168.00, 163.30, 161.51 (d, J = 244.8 Hz), 158.99, 142.10, 138.29, 131.46 
(d, J = 4.9 Hz), 128.86, 128.75, 128.70, 128.55, 126.08 (d, J = 16.0 Hz), 126.06, 124.60 (d, J 
= 3.5 Hz), 121.55, 115.75 (d, J = 22.0 Hz), 115.31, 61.46, 41.41, 41.16, 34.52, 29.03, 15.68, 
14.58. MS (ESI): calcd. 464.18; found 464.47 [M+H]+.
Ethyl 5-methyl-4-((4-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,m)
Isolated 103 mg (77% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.10 
(m, 9H), 5.61 (t, J = 5.3 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.88 (dd, J = 12.2, 6.6 Hz, 2H), 
3.24 – 3.13 (m, 4H), 2.95 (t, J = 6.7 Hz, 2H), 2.69 (s, 3H), 2.36 (s, 3H), 1.40 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 168.09, 163.33, 159.00, 142.11, 138.36, 136.59, 135.89, 
129.76, 128.96, 128.71, 128.56, 126.07, 121.45, 115.34, 61.44, 42.41, 41.19, 34.93, 34.57, 
21.32, 15.68, 14.59. MS (ESI): calcd. 460.21; found 460.47 [M+H]+.
Ethyl 5-methyl-4-((3-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,n)
Isolated 113 mg (84% yield) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ 7.34 – 
7.16 (m, 6H), 7.07 (m, 3H), 5.61 (t, J = 5.3 Hz, NH), 4.35 (q, J = 7.1 Hz, 2H), 3.89 (dd, J = 
12.2, 6.6 Hz, 2H), 3.19 (m, 4H), 2.95 (t, J = 6.7 Hz, 2H), 2.69 (s, 3H), 2.36 (s, 3H), 1.39 (t, J 
= 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.09, 163.31, 159.00, 142.11, 138.97, 
138.74, 138.33, 129.89, 129.03, 128.71, 128.56, 127.79, 126.09, 126.07, 121.46, 115.36, 
61.45, 42.36, 41.20, 35.29, 34.58, 21.66, 15.61, 14.58. MS (ESI): calcd. 460.21; found 
460.50 [M+H]+.
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Ethyl 5-methyl-4-((2-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,o)
Isolated 101 mg (75% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.33 – 
7.14 (m, 9H), 5.68 (t, J = 5.5 Hz, NH), 4.36 (q, J = 7.1 Hz, 2H), 3.87 (dd, J = 12.8, 7.0 Hz, 
2H), 3.19 (m, 4H), 3.01 (t, J = 7.1 Hz, 2H), 2.76 (s, 3H), 2.41 (s, 3H), 1.40 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 168.10, 163.32, 159.09, 142.07, 138.29, 137.10, 136.71, 
130.94, 129.79, 128.70, 128.57, 127.16, 126.48, 126.09, 121.56, 115.35, 61.47, 41.30, 
41.13, 34.69, 32.99, 19.71, 15.79, 14.59. MS (ESI): calcd. 460.21; found 460.47 [M+H]+.
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,p)
Isolated 70 mg (72% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 8.45 (d, J 
= 5.9 Hz, 2H), 7.25 (d, J = 6.0 Hz, 2H), 7.22 (m, 4H), 7.18 (br. t, J = 5.8 Hz, NH), 7.13 (m, 
1H), 4.28 (q, J = 7.1 Hz, 2H), 3.77 (dd, J = 13.5, 6.5 Hz, 2H), 3.10 – 3.05 (m, 2H), 3.03 – 
2.98 (m, 2H), 2.92 (dd, J = 10.3, 4.0 Hz, 2H), 2.81 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, DMSO) δ 168.27, 159.30, 150.69, 149.70, 140.91, 129.45, 127.00, 125.50, 
62.28, 42.30, 35.00, 34.48, 16.68, 15.37. MS (ESI): calcd. 447.185; found 447.20 [M+H]+.
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,q)
Isolated 54 mg (41% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 8.46 (s, 
1H), 8.41 (d, J = 4.5 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.31 (dd, J = 7.7, 4.8 Hz, 1H), 7.25 – 
7.21 (m, 4H), 7.19 – 7.12 (m, NH, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.76 (dd, J = 13.1, 6.7 Hz, 
2H), 3.10 – 3.05 (m, 2H), 3.00 (dd, J = 8.4, 6.2 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H), 2.81 (s, 
3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.19, 163.47, 159.26, 
151.00, 148.56, 142.66, 140.86, 137.49, 136.20, 129.41, 126.95, 124.63, 120.37, 115.78, 
62.21, 42.92, 41.25, 34.48, 32.87, 16.65, 15.32. MS (ESI): calcd. 447.185; found 447.27 [M
+H]+.
Ethyl 5-methyl-2-phenethyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(d,r)
Isolated 118 mg (90% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.52 (dd, 
J = 5.8, 1.7 Hz, 1H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.49 (s, NH), 7.31 – 7.23 (m, 4H), 7.21 – 
7.13 (m, 3H), 4.34 (q, J = 7.1 Hz, 2H), 4.02 (dd, J = 11.5, 5.2 Hz, 2H), 3.19 – 3.06 (m, 6H), 
2.97 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.08, 168.01, 163.46, 
160.33, 158.80, 149.13, 142.21, 139.20, 137.12, 128.71, 128.51, 126.00, 123.76, 122.02, 
120.96, 115.53, 61.35, 41.19, 40.27, 36.09, 34.56, 15.79, 14.60. MS (ESI): calcd. 447.19; 
found 447.40 [M+H]+.
Ethyl 4-((2,3-dihydro-1H-inden-2-yl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,x)
Isolated 105 mg (79% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.33 – 
7.17 (m, 9H), 5.82 (d, J = 6.7 Hz, NH), 5.13 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.52 (d, J = 
7.3 Hz, 2H), 3.46 (d, J = 7.2 Hz, 2H), 2.95 (d, J = 5.4 Hz, 2H), 2.89 (d, J = 5.5 Hz, 2H), 2.84 
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(s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.03, 163.28, 158.79, 
142.05, 141.03, 138.10, O128.71, 128.57, 127.14, 126.08, 125.10, 121.73, 115.31, 61.49, 
52.48, 41.12, 40.45, 34.57, 15.88, 14.58. MS (ESI): calcd. 458.19; found 458.47 [M+H]+.
Ethyl 4-((3,5-dimethoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylate 10(d,y)
Isolated 77 mg (52% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.23 (m, 
4H), 7.16 – 7.09 (m, 1H, NH), 6.41 (s, 2H), 6.33 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.73 (dd, J 
= 13.7, 6.3 Hz, 2H), 3.67 (s, 6H), 3.10 (m, 2H), 3.04 – 2.98 (m, 2H), 2.88 – 2.79 (m, 5H), 
1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 168.21, 168.18, 163.44, 161.61, 
159.23, 142.96, 142.67, 140.85, 129.39, 129.37, 126.94, 120.26, 115.78, 107.80, 99.12, 
62.15, 56.10, 43.39, 41.34, 36.05, 34.48, 16.60, 15.29. MS (ESI): calcd. 506.21; found 
506.53 [M+H]+
Ethyl 4-((2-(benzo[d][1,3]dioxol-5-yl)ethyl)amino)-5-methyl-2-phenethylthieno[2,3-
d]pyrimidine-6-carboxylate 10(d,z)
Isolated 94 mg (66% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 
7.20 (m, 4H), 7.10 (s, 1H, NH), 6.85 – 6.79 (m, 2H), 6.68 (d, J = 7.9 Hz, 1H), 5.95 (s, 2H), 
4.28 (q, J = 7.1 Hz, 2H), 3.69 (dd, J = 14.1, 6.3 Hz, 2H), 3.12 – 3.05 (m, 2H), 3.05 – 2.95 
(m, 2H), 2.85 – 2.78 (m, 5H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
168.19, 163.45, 159.23, 148.42, 146.70, 142.67, 140.87, 134.41, 129.40, 129.38, 126.94, 
122.67, 120.25, 115.76, 110.12, 109.30, 101.84, 62.15, 43.63, 41.32, 35.45, 34.49, 16.62, 
15.31. MS (ESI): calcd. 490.18; found 490.47 [M+H]+.
Ethyl 5-methyl-4-(methylamino)-2-(3-phenylpropyl)thieno[2,3-d]pyrimidine-6-carboxylate 
10(e,a)
Isolated 52 mg (33% yield) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 – 7.14 (m, 
5H), 5.67 (m, NH), 4.33 (q, J = 7.1 Hz, 2H), 3.12 (d, J = 4.8 Hz, 3H), 2.88 (s, 3H), 2.84 (m, 
2H), 2.75 – 2.67 (m, 2H), 2.22 – 2.11 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 168.72, 167.83, 163.32, 159.61, 142.63, 138.32, 128.75, 128.45, 125.88, 121.25, 
115.33, 61.42, 39.21, 35.91, 30.26, 28.33, 15.93, 14.56. MS (ESI): calcd. 370.159; found 
370.33 [M+H]+
Ethyl 5-methyl-4-(methylamino)-2-(4-phenylbutyl)thieno[2,3-d]pyrimidine-6-carboxylate 
10(f,a)
Isolated 88 mg (43 % yield) as a pale yellow syrup. 1H NMR (300 MHz, CDCl3) δ 7.29 – 
7.13 (m, 5H), 5.64 (br. m, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.11 (d, J = 4.8 Hz, 3H), 2.89 (s, 
3H), 2.88 – 2.81 (m, 2H), 2.70 – 2.63 (m, 2H), 1.95 – 1.83 (m, 2H), 1.78 – 1.67 (m, 2H), 
1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.96, 167.88, 163.35, 159.64, 
142.89, 138.27, 128.65, 128.43, 125.80, 121.27, 115.32, 61.42, 39.51, 36.06, 31.51, 28.30, 
15.95, 14.57. MS (ESI): calcd. 384.175; found 384.27 [M+H]+.
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Ethyl 2-(3-methoxyphenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(h,a)
Isolated 163 mg (83% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.16 (t, J 
= 7.8 Hz, 1H), 6.84 (m, 2H), 6.70 (dd, J = 8.1, 2.5 Hz, 1H), 5.66 (br. m, NH), 4.33 (q, J = 7.1 
Hz, 2H), 3.75 (s, 3H), 3.15 – 3.08 (m, 7H), 2.86 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 167.96, 163.29, 159.77, 159.61, 143.75, 138.29, 129.46, 121.37, 
121.09, 115.41, 114.25, 111.53, 61.44, 55.32, 41.06, 34.48, 28.32, 15.90, 14.56. MS (ESI): 
calcd. 386.154; found 386.27 [M+H]+.
Ethyl 2-(3-fluorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(k,a)
Isolated 141 mg (54% yield) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.21 – 7.13 
(m, 1H), 7.05 – 6.92 (m, 2H), 6.84 (td, J = 8.5, 2.6 Hz, 1H), 5.66 (br. m, NH), 4.33 (q, J = 
7.1 Hz, 2H), 3.17 – 3.06 (m, 7H), 2.88 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 167.80, 167.58, 164.66, 163.28, 161.41, 159.61, 144.70 (d, J = 7.2 Hz), 138.21, 
129.85 (d, J = 8.4 Hz), 124.34 (d, J = 2.6 Hz), 121.51, 115.42 (d, J = 3.6 Hz), 112.84 (d, J = 
21.0 Hz), 61.46, 40.67, 34.02, 28.32, 15.92, 14.54. MS (ESI): calcd. 374.134; found 374.20 
[M+H]+.
Ethyl 5-methyl-4-(methylamino)-2-(2-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidine-6-
carboxylate 10(q,a)
Isolated 585 mg (57% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.54 (ddd, J = 
5.0, 1.7, 0.8 Hz, 1H), 7.65 (td, J = 7.7, 1.8 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.17 (ddd, J = 
7.5, 5.0, 1.1 Hz, 1H), 5.68 (br. m, NH), 4.34 (q, J = 7.1 Hz, 2H), 3.45 – 3.35 (m, 2H), 3.29 
(m, 2H), 3.08 (d, J = 4.7 Hz, 3H), 2.91 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 167.41, 163.29, 161.18, 159.61, 148.18, 138.21, 137.73, 123.64, 121.71, 121.59, 
115.48, 61.47, 38.68, 35.79, 28.39, 15.96, 14.55. MS (ESI): calcd. 357.139; found 357.20 
[M+H]+.
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(s,a)
Isolated 38 mg (68% yield) as a beige solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NHAc), 
7.41 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 7.09 (m, NH), 4.27 (q, J = 7.1 Hz, 2H), 
3.02 – 2.94 (m, 7H), 2.86 (s, 3H), 1.98 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, CDCl3 + CD3OD) δ 174.50, 172.26, 171.43, 167.85, 164.01, 143.40, 142.04, 140.74, 
133.30, 125.53, 124.67, 119.90, 65.95, 45.18, 38.26, 32.49, 28.11, 19.95, 18.70. MS (ESI): 
calcd. 413.16; found 413.33 [M+H]+.
Ethyl 2-(4-acetamidophenethyl)-4-((2-aminoethyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylate 10(s,b)
Isolated 51 mg (83 % yield) as a white solid. 1H NMR (300 MHz, DMSO) δ 9.81 (s, 
NHAc), 7.43 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.07 – 6.96 (m, NH), 4.26 (q, J = 
7.0 Hz, 2H), 3.57 (dd, J = 11.0, 5.5 Hz, 2H), 3.23 (dd, J = 11.6, 6.1 Hz, 2H), 3.03 – 2.90 (m, 
4H), 2.86 (s, 3H), 1.99 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 
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167.69, 162.98, 159.06, 156.71, 140.62, 137.83, 136.80, 129.09, 119.63, 115.35, 78.38, 
61.67, 33.38, 24.59, 21.41, 16.11, 14.81. MS (ESI): calcd. 442.191; found 442.27 [M+H]+.
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,p)
Isolated 86 mg (68% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, 
NHAc), 8.46 (d, J = 4.7 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.24 (m, 2H, NH), 7.12 (d, J = 8.2 
Hz, 2H), 4.26 (q, J = 7.0 Hz, 2H), 3.76 (dd, J = 12.7, 6.4 Hz, 2H), 3.07 – 2.90 (m, 6H), 2.79 
(s, 3H), 2.00 (s, 3H), 1.28 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 169.24, 
168.18, 163.44, 159.18, 150.63, 149.67, 140.79, 138.35, 137.19, 129.51, 129.43, 129.38, 
125.41, 120.15, 115.75, 62.17, 46.92, 41.32, 34.98, 33.91, 25.05, 16.61, 15.28. MS (ESI): 
calcd. 504.207; found 504.13 [M+H]+.
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,q)
Isolated 79 mg (63% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, 
NHAc), 8.41 (d, J = 4.7 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.46 (m, J = 15.7, 8.4 Hz, 3H), 
7.30 (dd, J = 7.7, 4.8 Hz, 1H), 7.18 – 7.10 (m, 2H, NH), 4.27 (q, J = 7.0 Hz, 2H), 3.76 (dd, J 
= 12.9, 6.6 Hz, 2H), 3.06 – 2.91 (m, 6H), 2.80 (s, 3H), 2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, DMSO) δ 168.20, 163.45, 159.23, 151.01, 148.58, 140.83, 
137.41, 137.19, 136.19, 129.62, 129.52, 124.60, 120.22, 120.13, 115.75, 62.18, 47.02, 
33.93, 32.88, 27.10, 25.06, 16.63, 15.30. MS (ESI): calcd. 504.207; found 504.27 [M+H]+.
Ethyl 2-(4-acetamidophenethyl)-5-methyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(s,r)
Isolated 55 mg (44% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 9.83 (s, 
NHAc), 8.52 (d, J = 4.1 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.43 (m, 2H, NH), 7.28 (d, J = 7.4 
Hz, 1H), 7.24 (dd, J = 7.4, 4.9 Hz, 1H), 7.14 (d, J = 8.3 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 
3.88 (dd, J = 12.3, 6.4 Hz, 2H), 3.09 (m, 2H), 3.05 – 2.99 (m, 2H), 2.96 (dd, J = 8.2, 6.3 Hz, 
2H), 2.84 (s, 3H), 2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
169.20, 168.29, 168.13, 163.46, 160.72, 159.20, 150.13, 140.80, 138.33, 137.87, 137.24, 
129.56, 124.47, 122.79, 120.33, 120.14, 115.79, 62.17, 41.60, 41.33, 37.36, 33.85, 25.09, 
16.52, 15.31. MS (ESI): calcd. 504.207; found 504.20 [M+H]+.
Ethyl 2-(3-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(t,a)
Isolated 45 mg (81% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, 
NHAc), 7.47 (s, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.14 (t, J = 7.8 Hz, 1H), 7.11 (m, J = 4.5 Hz, 
NH), 6.90 (d, J = 7.6 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.04 – 2.94 (m, 7H), 2.87 (s, 3H), 
2.00 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3 + CD3OD) δ 174.50, 
172.26, 171.43, 167.85, 164.01, 143.40, 142.04, 140.74, 133.30, 125.53, 124.67, 119.90, 
65.95, 45.18, 38.26, 32.49, 28.11, 19.95, 18.70. MS (ESI): calcd. 413.16; found 413.30 [M
+H]+.
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Ethyl 2-(2-acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylate 10(u,a)
Isolated 35 mg (63% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.43 (s, 
NHAc), 7.29 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.08 (m, 
NH, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.03 (m, 2H), 2.97 (d, J = 4.5 Hz, 3H), 2.93 (m, 2H), 2.86 
(s, 3H), 2.03 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3 + CD3OD) δ 
175.11, 172.05, 171.24, 167.71, 164.02, 143.67, 139.66, 139.37, 134.36, 131.18, 130.57, 
130.32, 125.54, 120.05, 66.02, 44.45, 33.67, 32.49, 28.01, 19.89, 18.71. MS (ESI): calcd. 
413.16; found 413.10 [M+H]+.
Ethyl 2-(3-chlorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylate 
10(v,a)
Isolated 122 mg (47% yield) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (m, 
1H), 7.15 – 7.08 (m, 3H), 5.65 (br. m, NH), 4.32 (q, J = 7.1 Hz, 2H), 3.13 – 3.08 (m, 7H), 
2.87 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 167.77, 167.51, 163.26, 
159.59, 144.15, 138.23, 134.13, 129.73, 128.89, 126.89, 126.17, 121.49, 115.43, 61.46, 
40.65, 33.94, 28.33, 15.91, 14.55. MS (ESI): calcd. 390.104; found 390.20 [M+H]+.
Ethyl 5-methyl-4-(methylamino)-2-(3-(trifluoromethyl)phenethyl)thieno[2,3-d]pyrimidine-6-
carboxylate 10(w,a)
Isolated 128 mg (50% yield) as a pale yellow semi-solid. 1H NMR (300 MHz, CDCl3) δ 
7.52 (s, 1H), 7.37 (m, 3H), 5.66 (br. m, NH), 4.32 (q, J = 7.1 Hz, 2H), 3.25 – 3.11 (m, 4H), 
3.09 (d, J = 4.8 Hz, 3H), 2.87 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 167.77, 167.36, 163.25, 159.60, 142.95, 138.20, 132.09, 130.62 (d, J = 31.9 Hz), 128.88, 
125.52 (d, J = 3.8 Hz), 122.87 (d, J = 3.8 Hz), 121.55, 115.43, 61.46, 40.61, 34.04, 28.26, 
15.88, 14.51. MS (ESI): calcd. 424.131; found 424.27 [M+H]+.
Ethyl 2-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-5-methyl-4-(methylamino)thieno[2,3-
d]pyrimidine-6-carboxylate 10(z,a)
Isolated 62 mg (41% yield) as a pale yellow solid. 1H NMR (500 MHz, DMSO) δ 7.08 (m, 
NH), 6.81 (s, 1H), 6.76 (dd, J = 7.9, 2.0 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.92 (s, 2H), 4.27 
(q, J = 7.1 Hz, 2H), 3.33 (s, 3H), 3.02 – 2.93 (m, 7H), 2.86 (s, 3H), 1.28 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, DMSO) δ 168.23, 167.95, 163.50, 159.82, 148.24, 146.36, 
141.08, 136.55, 122.20, 120.06, 115.93, 109.95, 109.16, 101.71, 62.16, 41.56, 34.09, 29.27, 
16.73, 15.33. MS (ESI): calcd. 400.13; found 400.40 [M+H]+.
Dimethyl thiophene-2,5-dicarboxylate (13)
An ice-cooled pressure vessel was charged with thiophene-2,5-carboxylic acid (2.5 g, 14.5 
mmol) and 50 mL anhydrous MeOH; thionyl chloride (4.2 mL, 58 mmol) was added 
dropwise via syringe and once gas evolution had ceased the vessel was tightly sealed with a 
Teflon screw cap. The reaction was stirred 1h at RT and 3h at 60°C. The reaction mixture 
was cooled to RT and stirred open to air for 1h. The crude reaction mixture was diluted with 
100 mL DCM, stirred for 1h and decanted. The residue was collected by filtration and 
washed with DCM to obtain the desired product as a whit powder, 2.9 g (99% yield). 1H 
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NMR (300 MHz, DMSO) δ 7.81 (s, 2H), 3.85 (s, 6H). 13C NMR (126 MHz, DMSO) δ 
162.40, 139.25, 134.94, 53.99.
Dimethyl 3-aminothiophene-2,5-dicarboxylate (14)
An ice-cooled round-bottom flask was charged with 12 (1.0 g, 5.0 mmol), followed by 5 mL 
sulfuric acid. Nitric acid (0.50 mL, 6.2 mmol) was added slowly dropwise via syringe and 
the reaction was stirred at RT for 1 h. The crude reaction mixture was carefully poured on 
ice-water and stirred for 1h. The suspension was filtered, washed with water and dried on 
high vacuum to furnish dimethyl 3-nitrothiophene-2,5-dicarboxylate as a white solid, 1.1 g 
(93% yield). 1H NMR (500 MHz, DMSO) δ 8.22 (s, 1H), 3.88 (s, 6H). 13C NMR (126 
MHz, DMSO) δ 161.14, 159.81, 148.22, 136.58, 133.46, 129.26, 55.05, 54.53. A round-
bottom flask was charged with dimethyl 3-nitrothiophene-2,5-dicarboxylate (1.0 g, 4.1 
mmol), suspended in MeOH/THF 2:1 and purged with nitrogen. Pearlman’s catalyst was 
added (286 mg, 2.0 mmol, 20% Pd(OH)2/C, CAS 12135-22-7), and the reaction mixture was 
purged with H2 gas and equipped with an H2-filled balloon. The reaction was stirred at RT 
until complete consumption of starting material, as determined by TLC. The reaction 
mixture was purged with nitrogen and filtered through a plug of Celite, rinsing with EtOAc. 
The filtrate was concentrated in vacuo and the obtained material was used as such without 
further purification. Isolated 900 mg (100% yield) as a yellow powder. 1H NMR (500 MHz, 
DMSO) δ 7.22 (s, 1H), 6.62 (s, NH2), 3.80 (s, 3H), 3.74 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 164.82, 162.69, 155.01, 136.68, 126.34, 103.33, 53.84, 52.61.
Thienopyrimidinone formation, amine coupling and ester saponification performed as 
described in the general procedures.
Methyl 4-(methylamino)-2-phenethylthieno[3,2-d]pyrimidine-6-carboxylate 16(d,a)
Isolated 106 mg (51% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.98 (m, NH), 
7.84 (s, 1H), 7.22 (m, 4H), 7.12 (m, 1H), 3.87 (s, 3H), 3.13 – 3.04 (m, 4H), 2.98 (d, J = 4.5 
Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.61, 163.19, 159.25, 158.42, 142.92, 137.95, 
130.96, 129.43, 129.35, 126.84, 117.58, 54.06, 34.81, 26.99, 26.93. MS (ESI): calcd. 
328.11; found 328.27 [M+H]+.
Methyl 2-(3-methoxyphenethyl)-4-(methylamino)thieno[3,2-d]pyrimidine-6-carboxylate 
16(h,a)
Isolated 100 mg (64% yield) as a pale yellow oil. MS (ESI): calcd. 358.123; found 358.27 
[M+H]+
General procedure for the saponification of esters
To solution of ester (1 equivalent) in 2:1 THF/MeOH was added 1 M NaOH (3 equivalents) 
and water to bring the final solvent ratio to 2:1:1 THF/MeOH/H2O. In cases where the 
starting material was not fully dissolved, the solution was heated to 50 °C as necessary. The 
reaction was stirred at RT until complete consumption of starting material as determined by 
TLC. The reaction mixture was acidified to pH~3 with 1 M HCl and concentrated in vacuo. 
The resultant slurry was diluted with 5 mL water, filtered and washed successively with 
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deionized water, and purification grade pentane. The obtained residue was dried on high 
vacuum to furnish the desired free carboxylic acids.
5-Methyl-4-(methylamino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (17)
Isolated 32 mg (87% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.23 
(m, 4H), 7.16 (m, 1H), 7.07 (br. d, J = 4.4 Hz, NH), 3.10 – 3.06 (m, 2H), 3.02 – 2.98 (m, 
5H), 2.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.82, 166.58, 164.06, 158.71, 141.62, 
138.94, 128.33, 128.26, 125.79, 120.64, 115.00, 40.18, 33.32, 28.11, 15.44. HRMS (ESI): 
calcd. 328.11197 for C17H18N3O2S; found 328.1112 [M+H]+.
4-((2-Aminoethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid 
(18)
Isolated 15 mg (35% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.28 – 7.14 
(m, 4H), 7.04 (br. s, NH), 3.51 (m, 2H), 3.28 (m, 2H), 3.12 – 3.03 (m, 2H), 3.06 – 2.93 (m, 
5H), 2.58 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.91, 166.32, 163.82, 158.03, 142.57, 
139.42, 128.65, 128.97, 126.02, 120.41, 114.63, 47.69, 41.31, 33.89, 25.16, 16.46. HRMS 
(ESI): calcd. 357.13852 for C18H21N4O2S; found 357.1389 [M+H]+.
4-(Benzylamino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (19)
Isolated 40 mg (86% yield) as a white crystalline material. 1H NMR (500 MHz, DMSO) δ 
7.96 (br. s, NH), 7.41 (d, J = 7.1 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.25 – 7.21 (m, 1H), 7.19 
(d, J = 7.5 Hz, 2H), 7.15 – 7.08 (m, 3H), 4.79 (d, J = 5.8 Hz, 2H), 2.96 (m, 4H), 2.95 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 164.72, 163.63, 157.97, 140.85, 139.07, 138.84, 
128.29, 128.29, 128.25, 127.47, 126.84, 125.94, 122.31, 115.31, 44.39, 38.54, 32.66, 15.43. 
HRMS (ESI): calcd. 404.14327 for C23H22N3O2S; found 404.1432 [M+H]+.
5-Methyl-2-phenethyl-4-(phenethylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid (20)
Isolated 28 mg (60% yield) as a white crystalline material. 1H NMR (500 MHz, DMSO) δ 
7.34 – 7.19 (m, 9H), 7.17 – 7.13 (m, 1H), 7.11 (br. t, J = 5.7 Hz, NH), 3.74 (dd, J = 14.6, 6.0 
Hz, 2H), 3.11 (dd, J = 8.5, 6.3 Hz, 2H), 3.03 (dd, J = 8.5, 6.2 Hz, 2H), 2.95 – 2.89 (m, 2H), 
2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.79, 164.03, 158.14, 141.56, 139.58, 
138.76, 128.73, 128.45, 128.30, 128.28, 126.19, 125.83, 120.89, 114.87, 42.33, 40.13, 
34.66, 33.37, 15.33. HRMS (ESI): calcd. 418.15892 for C24H24N3O2S; found 418.1557 [M
+H]+.
4-((4-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (21)
Isolated 36 mg (55% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.52 (m, 
NH), 7.27 – 7.22 (m, 4H), 7.15 (m, J = 7.5 Hz, 3H), 6.86 (d, J = 8.7 Hz, 2H), 3.72 (dd, J = 
14.3, 6.4 Hz, 2H), 3.70 (s, 3H), 3.13 – 3.09 (m, 2H), 3.06 (m, 2H), 2.87 – 2.82 (m, 2H), 2.82 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 164.45, 158.96, 158.84, 141.58, 139.77, 131.93, 
130.86, 129.57, 129.40, 127.30, 116.56, 115.02, 56.16, 44.42, 34.63, 33.54, 16.15. HRMS 
(ESI): calcd. 448.16949 for C25H26N3O3S; found 448.1695 [M+H]+.
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4-((3-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (22)
Isolated 45 mg (68% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.31 (m, 
NH), 7.25 – 7.19 (m, 5H), 7.16 – 7.12 (m, 1H), 6.81 (m, 2H), 6.77 (m, 1H), 3.75 (dd, J = 
14.0, 6.4 Hz, 2H), 3.69 (s, 3H), 3.13 – 3.08 (m, 2H), 3.06 – 3.01 (m, 2H), 2.88 (t, J = 7.4 Hz, 
2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.79, 160.49, 159.06, 142.11, 141.96, 
139.82, 130.61, 129.49, 129.39, 127.13, 122.13, 116.29, 115.49, 112.80, 56.01, 43.78, 
35.68, 34.00, 16.28. HRMS (ESI): calcd. 448.16949 for C25H26N3O3S; found 448.1684 [M
+H]+.
4-((2-Methoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (23)
Isolated 28 mg (60% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.26 – 
7.13 (m, 7H, NH), 6.95 (d, J = 7.7 Hz, 1H), 6.86 (t, J = 7.3 Hz, 1H), 3.73 (m, 5H), 3.10 (m, 
2H), 3.01 (m, 2H), 2.92 (t, J = 7.1 Hz, 2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
164.67, 159.08, 158.45, 141.93, 139.86, 131.43, 129.53, 129.39, 128.95, 128.07, 127.19, 
121.48, 116.36, 111.85, 56.38, 42.62, 33.72, 30.29, 16.20. HRMS (ESI): calcd. 448.16949 
for C25H26N3O3S; found 448.1681 [M+H]+.
4-((4-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (24)
Isolated 23 mg (35% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.28 – 
7.20 (m, 5H, NH), 7.12 (m, 4H), 3.71 (dd, J = 13.8, 6.2 Hz, 2H), 3.11 – 3.06 (m, 2H), 3.03 – 
2.98 (m, 2H), 2.89 (t, J = 7.4 Hz, 2H), 2.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 165.01, 
162.00 (d, J = 241.5 Hz), 159.18, 142.45, 139.87, 136.73 (d, J = 3.0 Hz), 131.63 (d, J = 7.9 
Hz), 129.44, 129.40, 127.01, 116.24 (d, J = 21.0 Hz), 116.08, 43.52, 34.82, 34.30, 16.41. 
HRMS (ESI): calcd. 436.14950 for C24H23FN3O2S; found 436.1473 [M+H]+.
4-((3-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (25)
Isolated 30 mg (46% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.41 (m, 
NH), 7.32 (dd, J = 14.4, 7.8 Hz, 1H), 7.26 – 7.21 (m, 4H), 7.16 – 7.12 (m, 1H), 7.07 (m, 
2H), 7.02 (td, J = 8.8, 2.5 Hz, 1H), 3.77 (dd, J = 13.9, 6.3 Hz, 2H), 3.12 – 3.07 (m, 2H), 3.06 
– 3.02 (m, 2H), 2.93 (t, J = 7.3 Hz, 2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
164.44, 163.37 (d, J = 243.2 Hz), 158.87, 143.12 (d, J = 7.4 Hz), 141.59, 139.72, 131.41 (d, 
J = 8.3 Hz), 129.54, 129.39, 127.28, 126.12, 126.10, 124.37, 116.64 (d, J = 14.6 Hz), 
116.54, 114.25 (d, J = 20.8 Hz), 43.76, 38.43, 35.12, 33.58, 16.14. HRMS (ESI): calcd. 
436.14950 for C24H23FN3O2S; found 436.1479 [M+H]+.
4-((2-Fluorophenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (26)
Isolated 21 mg (32% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.32 – 
7.19 (m, 6H, NH), 7.12 (m, 3H), 3.76 (dd, J = 13.8, 6.7 Hz, 2H), 3.08 (m, 2H), 3.02 – 2.93 
(m, 4H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.90, 161.97 (d, J = 243.3 Hz), 
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159.18, 142.33, 139.88, 132.52 (d, J = 5.0 Hz), 129.59, 129.53, 129.47, 129.39, 127.10 (d, J 
= 16.1 Hz), 127.06, 125.55 (d, J = 3.3 Hz), 116.32 (d, J = 21.8 Hz), 116.16, 42.24, 34.08, 
29.25, 16.34. HRMS (ESI): calcd. 436.14950 for C24H23FN3O2S; found 436.1476 [M+H]+.
5-Methyl-4-((4-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (27)
Isolated 48 mg (73% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.33 (m, 
NH), 7.26 – 7.21 (m, 4H), 7.16 – 7.09 (m, 5H), 3.72 (dd, J = 14.4, 6.2 Hz, 2H), 3.12 – 3.08 
(m, 2H), 3.06 – 3.02 (m, 2H), 2.88 – 2.83 (m, 2H), 2.81 (s, 3H), 2.25 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 164.64, 158.94, 141.90, 139.78, 137.16, 136.36, 130.15, 129.73, 129.52, 
129.38, 127.19, 116.37, 44.09, 35.17, 33.81, 21.80, 16.25. HRMS (ESI): calcd. 432.17457 
for C25H26N3O2S; found 432.1719 [M+H]+.
5-Methyl-4-((3-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (28)
Isolated 42 mg (64% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.45 (m, 
NH), 7.25 – 7.22 (m, 4H), 7.20 – 7.13 (m, 2H), 7.07 (s, 1H), 7.02 (m, 2H), 3.74 (dd, J = 
14.6, 6.1 Hz, 2H), 3.12 (m, 2H), 3.06 (m, 2H), 2.89 – 2.84 (m, 2H), 2.81 (s, 3H), 2.25 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 164.43, 158.82, 141.57, 140.02, 139.73, 138.61, 
130.58, 129.56, 129.50, 129.38, 128.09, 127.30, 126.94, 116.59, 44.26, 38.35, 35.44, 33.55, 
22.15, 16.12. HRMS (ESI): calcd. 432.17457 for C25H26N3O2S; found 432.1728 [M+H]+.
5-Methyl-4-((2-methylphenethyl)amino)-2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic 
acid (29)
Isolated 55 mg (84% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.42 (m, 
NH), 7.27 – 7.21 (m, 4H), 7.17 – 7.12 (m, 3H), 7.12 – 7.08 (m, 2H), 3.68 (dd, J = 15.5, 5.8 
Hz, 2H), 3.11 – 3.06 (m, 2H), 3.04 – 2.99 (m, 2H), 2.93 – 2.88 (m, 2H), 2.85 (s, 3H), 2.40 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 164.75, 159.07, 142.05, 139.79, 138.43, 137.20, 
131.24, 130.55, 129.52, 129.33, 127.51, 127.16, 127.08, 116.25, 42.76, 34.25, 33.47, 20.10, 
16.39. HRMS (ESI): calcd. 432.17457 for C25H26N3O2S; found 432.1746 [M+H]+.
5-Methyl-2-phenethyl-4-((2-(pyridin-4-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (30)
Isolated 42 mg (64% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.47 (d, J = 
5.8 Hz, 2H), 7.28 (d, J = 5.7 Hz, 2H), 7.25 – 7.20 (m, 4H), 7.13 (m, NH, 1H), 3.77 (dd, J = 
13.4, 6.6 Hz, 2H), 3.09 – 3.05 (m, 2H), 3.00 (m, 2H), 2.93 (t, J = 7.2 Hz, 2H), 2.80 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 168.00, 167.89, 165.14, 159.23, 150.30, 142.65, 
139.84, 129.42, 129.41, 126.95, 125.59, 122.11, 116.00, 42.20, 41.19, 35.03, 34.47, 16.48. 
HRMS (ESI): calcd. 419.15417 for C23H23N4O2S; found 419.1537 [M+H]+.
5-Methyl-2-phenethyl-4-((2-(pyridin-3-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (31)
Isolated 41 mg (87% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.45 (s, 1H), 
8.40 (d, J = 4.7 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.30 (dd, J = 7.7, 4.8 Hz, 1H), 7.25 – 7.20 
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(m, 4H), 7.13 (m, 1H, NH), 3.75 (dd, J = 13.3, 6.7 Hz, 2H), 3.07 (dd, J = 8.4, 6.1 Hz, 2H), 
2.99 (dd, J = 8.5, 6.3 Hz, 2H), 2.92 (t, J = 7.2 Hz, 2H), 2.80 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 168.00, 167.89, 165.15, 159.25, 151.01, 148.56, 142.67, 139.82, 137.49, 136.22, 
129.41, 126.94, 124.63, 122.11, 115.97, 42.86, 41.23, 34.49, 32.89, 16.47. HRMS (ESI): 
calcd. 419.15417 for C23H23N4O2S; found 419.1537 [M+H]+.
5-Methyl-2-phenethyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (32)
Isolated 57 mg (87% yield) as an off white solid. 1H NMR (500 MHz, DMSO) δ 8.56 (d, J 
= 4.9 Hz, 1H), 7.83 (m, NH), 7.41 – 7.32 (m, 3H), 7.24 – 7.21 (m, 4H), 7.15 – 7.11 (m, 1H), 
3.89 (dd, J = 12.4, 6.6 Hz, 2H), 3.12 (t, J = 6.7 Hz, 2H), 3.05 (m, 2H), 2.96 (m, 2H), 2.84 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 167.80, 165.14, 159.92, 159.17, 148.62, 142.70, 
139.82, 139.46, 129.42, 129.38, 126.90, 125.32, 123.35, 122.12, 115.99, 41.44, 41.17, 
36.77, 34.40, 16.42. MS (ESI): calcd. 419.15417 for C23H23N4O2S; found 419.1545 [M
+H]+
2-(4-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (33)
Isolated 27 mg (72% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 9.85 (s, 
NHAc), 7.46 (m, NH), 7.44 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.3 Hz, 2H), 3.03 (m, 7H), 2.87 
(s, 3H), 1.99 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.25, 164.47, 159.15, 139.96, 
138.66, 136.03, 129.62, 124.20, 120.16, 116.72, 38.55, 33.04, 30.12, 25.10, 16.22. HRMS 
(ESI): calcd. 385.13344 for C19H21N4O3S; found 385.1336 [M+H]+.
2-(3-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (34)
Isolated 23 mg (62% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, 
NHAc), 7.47 (s, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.15 (t, J = 7.8 Hz, 1H), 7.08 (m, NH), 6.90 
(d, J = 7.9 Hz, 1H), 3.05 – 2.94 (m, 7H), 2.86 (s, 3H), 2.00 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 169.33, 167.60, 165.14, 159.80, 143.12, 140.46, 140.07, 129.69, 124.16, 121.93, 
120.00, 117.75, 116.19, 34.57, 29.33, 25.18, 16.55. HRMS (ESI): calcd. 385.13344 for 
C19H21N4O3S; found 385.1333 [M+H]+.
2-(2-Acetamidophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic 
acid (35)
Isolated 13 mg (46% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 9.40 (s, 
NHAc), 7.32 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.14 (m, NH), 7.08 (m, 2H), 3.08 
– 3.02 (m, 2H), 2.98 (d, J = 4.4 Hz, 3H), 2.96 – 2.91 (m, 2H), 2.86 (s, 3H), 2.04 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 169.54, 168.12, 165.17, 159.83, 140.10, 137.22, 136.98, 130.26, 
127.28, 126.57, 121.82, 116.18, 30.04, 29.25, 24.42, 16.58. HRMS (ESI): calcd. 385.13344 
for C19H21N4O3S; found 385.1331 [M+H]+.
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4-((2,3-Dihydro-1H-inden-2-yl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylic acid (36)
Isolated 47 mg (72% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.25 – 
7.19 (m, 5H, NH), 7.17 – 7.12 (m, 3H), 6.91 (d, J = 7.0 Hz, 1H), 5.07 – 4.98 (m, 1H), 3.36 – 
3.28 (m, 2H), 3.09 – 3.04 (m, 3H), 3.01 (m, 3H), 2.87 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 168.05, 167.84, 165.15, 159.46, 142.65, 142.33, 140.06, 129.41, 129.37, 127.58, 126.91, 
125.53, 122.21, 116.24, 53.03, 41.21, 39.86, 34.49, 16.39. HRMS (ESI): calcd. 430.15892 
for C25H24N3O2S; found 430.1562 [M+H]+.
4-((3,5-Dimethoxyphenethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylic acid (37)
Isolated 31 mg (82% yield) as an off white powder. 1H NMR (500 MHz, DMSO) δ 7.24 – 
7.22 (m, 4H), 7.16 – 7.09 (m, 1H, NH), 6.41 (d, J = 2.2 Hz, 2H), 6.33 (t, J = 2.2 Hz, 1H), 
3.73 (dd, J = 14.5, 6.4 Hz, 2H), 3.67 (s, 6H), 3.10 (m, 2H), 3.01 (m, 2H), 2.87 – 2.82 (m, 
2H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 165.08, 161.61, 159.21, 142.94, 142.57, 
139.84, 129.42, 129.38, 126.99, 116.05, 107.83, 99.15, 56.13, 43.42, 36.02, 34.40, 16.41. 
MS (ESI): calcd. 478.18005 for C26H28N3O4S; found 478.1782 [M+H]+.
4-((2-(Benzo[d][1,3]dioxol-5-yl)ethyl)amino)-5-methyl-2-phenethylthieno[2,3-d]pyrimidine-6-
carboxylic acid (38)
Isolated 22 mg (47% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.27 – 7.18 (m, 
5H, NH), 7.16 – 7.12 (m, 1H), 6.82 (m, 2H), 6.68 (dd, J = 7.9, 1.6 Hz, 1H), 5.95 (s, 2H), 
3.70 (dd, J = 14.0, 6.0 Hz, 1H), 3.13 – 3.06 (m, 2H), 3.02 (m, 2H), 2.85 – 2.78 (m, 5H). 13C 
NMR (126 MHz, DMSO) δ 164.83, 159.07, 148.43, 146.76, 142.18, 139.85, 134.16, 129.49, 
129.40, 127.12, 122.76, 116.24, 110.19, 109.33, 101.86, 43.92, 35.33, 34.07, 16.31. HRMS 
(ESI): calcd. 462.14875 for C25H24N3O4S; found 462.1486 [M+H]+.
5-Methyl-4-(methylamino)-2-(3-phenylpropyl)thieno[2,3-d]pyrimidine-6-carboxylic acid (39)
Isolated 36 mg (78% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.25 (m, 
2H), 7.19 (m, 2H), 7.14 (m, 1H, NH), 2.97 (d, J = 4.4 Hz, 3H), 2.84 (s, 3H), 2.69 (t, J = 7.5 
Hz, 2H), 2.62 (t, J = 7.6 Hz, 2H), 2.05 – 1.97 (m, 2H). 13C NMR (126 MHz, DMSO) δ 
168.13, 165.10, 159.76, 143.09, 140.03, 129.53, 129.38, 126.84, 121.96, 116.11, 38.83, 
35.90, 30.49, 29.34, 16.50. MS (ESI): calcd 342.12762 for C18H20N3O2S; found 342.1256 
[M+H]+.
5-Methyl-4-(methylamino)-2-(4-phenylbutyl)thieno[2,3-d]pyrimidine-6-carboxylic acid (40)
Isolated 60 mg (86% yield) as white powder. 1H NMR (500 MHz, DMSO) δ 7.23 (t, J = 7.5 
Hz, 2H), 7.13 (m, 3H), 7.03 (br. m, NH), 2.94 (d, J = 4.4 Hz, 3H), 2.84 (s, 3H), 2.69 (t, J = 
7.5 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 1.76 – 1.68 (m, 2H), 1.63 – 1.55 (m, 2H). 13C NMR 
(126 MHz, DMSO) δ 168.72, 167.39, 165.17, 159.83, 143.33, 140.06, 129.42, 129.34, 
126.74, 121.71, 116.03, 39.49, 36.12, 31.86, 29.21, 28.41, 16.53. HRMS (ESI): calcd 
356.14327 for C19H22N3O2S; found 356.1413 [M+H]+.
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2-(3-Methoxyphenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(41)
Isolated 66 mg (71% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.12 (t, J = 
8.0 Hz, 1H), 7.01 (m, NH), 6.77 (m, 2H), 6.68 (dd, J = 9.0, 1.6 Hz, 1H), 3.05 – 2.93 (m, 7H), 
2.82 (s, 3H). OCH3 signal obscured by water peak. 13C NMR (126 MHz, DMSO) δ 167.90, 
167.48, 165.15, 160.29, 159.80, 144.29, 140.03, 130.39, 121.82, 121.70, 116.09, 115.03, 
112.39, 55.95, 41.03, 34.37, 29.19, 16.48. MS (ESI): calc. 358.12254 for C18H20N3O3S; 
found 358.1208 [M+H]+.
2-(3-Fluorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(42)
Isolated 77 mg (83% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.24 (m, 
1H), 7.02 (m, 2H, NH), 6.93 (m, 1H), 3.06 (t, J = 7.5 Hz, 2H), 3.00 – 2.95 (m, 2H), 2.94 (d, 
J = 4.5 Hz, 3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.64, 167.50, 165.14, 
163.28 (d, J = 242.8 Hz), 159.77, 145.69 (d, J = 7.3 Hz), 140.01, 131.16 (d, J = 8.4 Hz), 
125.58 (d, J = 2.6 Hz), 121.85, 116.12 (d, J = 20.7 Hz), 116.09, 113.65 (d, J = 20.9 Hz), 
40.65, 33.89, 29.17, 16.47. HRMS (ESI): calcd. 346.10255 for C17H17FN3O2S; found 
346.1006 [M+H]+.
5-Methyl-4-(methylamino)-2-(2-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(43)
Isolated 46 mg (84% yield) as a white powder. 1H NMR (300 MHz, DMSO) δ 8.75 (d, J = 
4.9 Hz, 1H), 8.41 (td, J = 7.9, 1.5 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.82 (t, J = 6.3 Hz, 1H), 
7.17 (br. m, NH), 3.47 (t, J = 7.1 Hz, 2H), 3.27 (t, J = 7.1 Hz, 2H), 2.80 (m, 6H). 13C NMR 
(75 MHz, DMSO) δ 165.80, 165.33, 164.51, 159.13, 157.64, 146.10, 142.19, 139.47, 
127.38, 125.11, 121.94, 115.76, 36.57, 31.33, 28.73, 15.89. HRMS (ESI): calcd. 329.10722 
for C16H17N4O2S; found 329.1067 [M+H]+.
2-(4-Acetamidophenethyl)-4-((2-aminoethyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylic acid (44)
Isolated 17 mg (36% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.84 (s, 
NHAc), 8.50 (br. s, NH2), 7.56 (br. s, NH), 7.44 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 
3.82 (m, 2H), 3.15 (m, 2H), 3.03 (s, 3H), 3.00 (d, J = 7.2 Hz, 2H), 2.94 (d, J = 7.8 Hz, 2H), 
2.00 (s, 3H). HRMS (ESI): calcd. 414.15999 for C20H24N5O3S; found 414.1591 [M+H]+.
2-(4-Acetamidophenethyl)-5-methyl-4-((2-(pyridin-2-yl)ethyl)amino)thieno[2,3-
d]pyrimidine-6-carboxylic acid (45)
Isolated 33 mg (64% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.83 (s, NH), 
8.51 (d, J = 4.9 Hz, 1H), 7.71 (tt, J = 7.7, 1.9 Hz, 1H), 7.42 (d, J = 6.8 Hz, 2H), 7.36 (br. t, J 
= 4.8 Hz, NH), 7.28 (d, J = 7.8 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.13 (d, J = 6.9 Hz, 2H), 3.87 
(dd, J = 12.2, 5.5 Hz, 2H), 3.08 (t, J = 6.5 Hz, 2H), 3.04 – 2.99 (m, 2H), 2.97 – 2.93 (m, 2H), 
2.85 (s, 3H), 1.99 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.20, 167.80, 165.22, 160.73, 
159.22, 150.13, 138.30, 137.87, 137.25, 129.57, 124.49, 122.79, 120.13, 116.03, 41.56, 
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41.31, 37.42, 33.89, 25.07, 16.32. HRMS (ESI): calcd. 476.17564 for C25H26N5O3S; found 
476.1761 [M+H]+
2-(3-Chlorophenethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid 
(46)
Isolated 62 mg (67% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.28 (s, 1H), 
7.25 – 7.21 (m, 1H), 7.18 – 7.14 (m, 2H), 7.03 (m, NH), 3.07 – 3.02 (m, 2H), 2.97 (m, 2H), 
2.94 (d, J = 4.5 Hz, 3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.47, 167.21, 
165.11, 159.74, 145.25, 140.00, 133.93, 131.16, 129.37, 128.21, 126.90, 121.93, 116.10, 
40.51, 33.75, 29.20, 16.46. HRMS (ESI): calcd. 362.07300 for C17H17ClN3O2S; found 
362.0719 [M+H]+.
5-Methyl-4-(methylamino)-2-(3-(trifluoromethyl)phenethyl)thieno[2,3-d]pyrimidine-6-
carboxylic acid (47)
Isolated 80 mg (86% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 7.55 (s, 1H), 
7.46 (m, 3H), 7.04 (br. m, NH), 3.14 (t, J = 7.5 Hz, 2H), 3.02 (t, J = 7.5 Hz, 2H), 2.92 (d, J = 
4.4 Hz, 3H), 2.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.36, 167.13, 165.10, 159.73, 
144.05, 139.97, 133.66, 130.31, 130.16, 129.91, δ 126.06 (q, J = 3.8 Hz), 123.66 (q, J = 3.9 
Hz), 121.96, 116.09, 33.79, 29.14, 16.44. HRMS (ESI): calcd. 396.09936 for 
C18H17F3N3O2S; found 396.0975 [M+H]+.
2-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-5-methyl-4-(methylamino)thieno[2,3-d]pyrimidine-6-
carboxylic acid (48)
Isolated 25 mg (54% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.13 (br. s, NH), 
6.82 (s, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.93 (s, 2H), 3.02 – 2.93 (m, 
7H), 2.86 (s, 3H). 13C NMR (126 MHz, DMSO) δ 167.45, 165.09, 159.73, 148.25, 146.39, 
140.07, 136.42, 122.21, 122.05, 116.18, 109.95, 109.18, 101.72, 41.21, 34.01, 29.36, 16.53. 
HRMS (ESI): calcd. 372.10180 for C18H18N3O4S; found 372.1021 [M+H]+.
4-(methylamino)-2-phenethylthieno[3,2-d]pyrimidine-6-carboxylic acid (49)
Isolated 40 mg (84% yield) as an off-white powder. 1H NMR (500 MHz, DMSO) δ 7.99 (m, 
NH), 7.81 (s, 1H), 7.27 – 7.23 (m, 4H), 7.16 (m, 1H), 3.12 – 3.07 (m, 2H), 3.05 – 3.01 (m, 
2H), 2.99 (d, J = 4.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.38, 164.21, 158.49, 
142.88, 130.23, 129.48, 129.39, 126.90, 41.32, 34.82, 28.44. HRMS (ESI): calcd. 314.09632 
for C16H16N3O2S; found 314.0962 [M+H]+.
2-(3-Methoxyphenethyl)-4-(methylamino)thieno[3,2-d]pyrimidine-6-carboxylic acid (50)
Isolated 78 mg (81% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 8.11 (br. d, J 
= 4.3 Hz, 1H), 7.76 (s, 1H), 7.13 (t, J = 7.8 Hz, 1H), 6.81 – 6.75 (m, 2H), 6.68 (dd, J = 8.3, 
1.7 Hz, 1H), 3.04 – 2.99 (m, 4H), 2.97 (d, J = 4.4 Hz, 3H). OCH3 signal obscured by water 
peak. 13C NMR (126 MHz, DMSO) δ 167.10, 164.14, 160.30, 144.29, 130.40, 129.32, 
121.72, 121.68, 115.03, 112.40, 55.95, 40.79, 34.69. HRMS (ESI): calcd. 344.10689 for 
C17H18N3O3S; found 344.1072 [M+H]+.
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Ethyl 4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate – 51 (precursor)
Isolated 101 mg (53% yield) as a colorless syrup. 1H NMR (500 MHz, DMSO) δ 7.38 (m, 
2H), 7.34 – 7.28 (m, ), 7.22 (m, 5H), 7.10 (t, J = 6.8 Hz, 1H), 6.96 (br. t, J = 5.5 Hz, NH), 
4.54 (dd, J = 7.5, 5.3 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.76 – 3.69 (m, 1H), 3.69 – 3.61 (m, 
1H), 3.43 (m, 1H), 3.18 (s, 3H), 2.96 (m, 2H), 2.76 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.20 (d, 
J = 6.9 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 167.65, 167.15, 162.87, 158.58, 147.31, 
140.51, 140.03, 129.07, 128.85, 128.46, 127.41, 127.19, 126.50, 120.06, 115.15, 81.57, 
79.84, 61.61, 57.16, 47.51, 39.04, 22.62, 15.94, 14.75. MS (ESI): calcd. 490.22; found 
490.33 [M+H]+.
4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (51)
Isolated 13 mg (28% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.38 (m, 2H), 
7.31 (m, 3H), 7.22 (m, 4H), 7.12 – 7.08 (m, 1H), 6.85 (br. s, NH), 4.54 (m, 1H), 3.72 (m, 
1H), 3.68 – 3.60 (m, 1H), 3.18 (s, 3H), 3.02 – 2.86 (m, 3H), 2.75 (s, 3H), 1.20 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, DMSO) δ 167.68, 167.10, 165.30, 159.07, 147.85, 141.06, 
129.60, 129.40, 128.99, 127.97, 127.75, 127.04, 115.94, 82.06, 57.70, 47.98, 47.61, 39.57, 
23.21, 16.17. HRMS (ESI): calcd. 462.18514 for C26H28N3O3S; found 462.1853 [M+H]+
Ethyl 4-(((S)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 52 (precursor)
Isolated 31 mg (16% yield) as a colorless syrup. 1H NMR (500 MHz, DMSO) δ 7.41 – 7.36 
(m, 2H), 7.31 (m, 3H), 7.25 – 7.20 (m, 4H), 7.10 (m, 1H), 6.99 (br. t, J = 5.4 Hz, NH), 4.51 
(dd, J = 7.8, 4.7 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.79 – 3.73 (m, 1H), 3.62 (m, 1H), 3.44 
(m, 1H), 3.17 (s, 3H), 2.95 (m, 2H), 2.78 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.22 (d, J = 7.0 
Hz, 3H). 13C NMR (75 MHz, DMSO) δ 167.62, 167.17, 162.90, 158.60, 147.27, 140.52, 
140.12, 129.11, 128.88, 128.51, 127.45, 127.20, 126.54, 120.05, 115.17, 81.63, 61.68, 
57.21, 47.49, 36.87, 24.96, 22.71, 16.00, 14.80. MS (ESI): calcd. 490.22; found 490.40 [M
+H]+.
4-(((S)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((S)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (52)
Isolated 15 mg (53% yield) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.39 (m, 2H), 
7.31 (m, 3H), 7.21 (m, 4H), 7.10 (m, 1H), 6.97 (m, NH), 4.51 (dd, J = 7.7, 4.4 Hz, 1H), 3.76 
(m, 1H), 3.62 (m, 1H), 3.17 (s, 3H), 2.95 (m, 3H), 2.77 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, DMSO) δ 167.30, 165.07, 159.10, 147.75, 141.02, 139.64, 129.62, 129.40, 
129.02, 127.97, 127.73, 127.07, 122.30, 115.88, 82.12, 57.72, 47.89, 47.70, 39.49, 23.24, 
16.32. HRMS (ESI): calcd. 462.18514 for C26H28N3O3S; found 462.1857 [M+H]+.
Ethyl 4-(((R)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 53 (precursor)
Isolated 65 mg (63% yield) as pale yellow syrup. 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.20 
(m, 9H), 7.16 – 7.09 (m, 1H), 6.11 (br. t, NH), 4.41 – 4.31 (m, 3H), 4.08 (ddd, J = 13.8, 7.2, 
De Schutter et al. Page 30
J Med Chem. Author manuscript; available in PMC 2017 July 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4.0 Hz, 1H), 3.56 – 3.44 (m, 2H), 3.30 (s, 3H), 3.17 – 2.96 (m, 2H), 2.87 (s, 3H), 1.39 (t, J = 
7.1 Hz, 3H), 1.29 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.33, 158.77, 
147.18, 139.30, 138.36, 128.97, 128.57, 128.47, 127.27, 126.87, 126.13, 115.37, 82.07, 
61.45, 57.25, 47.11, 39.30, 24.96, 22.09, 15.71, 14.56. MS (ESI): calcd. 490.22; found 
490.33 [M+H]+.
4-(((R)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (53)
Isolated 43 mg (76% yield) as white solid. 1H NMR (500 MHz, DMSO) δ 7.39 (m, 2H), 
7.31 (m, 3H), 7.25 – 7.18 (m, 4H), 7.12 – 7.07 (m, 1H), 7.04 ( br. t, J = 5.4 Hz, NH), 4.50 
(dd, J = 7.9, 4.7 Hz, 1H), 3.80 – 3.73 (m, 1H), 3.66 – 3.61 (m, 1H), 3.17 (s, 3H), 2.96 (m, 
4H), 2.77 (s, 3H), 1.22 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.06, 165.01, 
159.08, 147.65, 140.95, 139.63, 129.63, 129.42, 129.04, 127.96, 127.73, 127.10, 122.47, 
115.92, 82.10, 68.17, 57.72, 47.73, 39.47, 23.22, 16.28. HRMS (ESI): calcd. 462.18514 for 
C26H28N3O3S; found 462.1847 [M+H]+.
Ethyl 4-(((S)-2-methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylate 54 (precursor)
Isolated 67 mg (65% yield) as a colorless syrup. 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.32 
(m, 5H), 7.30 – 7.19 (m, 4H), 7.13 (dt, J = 9.3, 4.2 Hz, 1H), 6.11 (br. t, NH), 4.39 (m, 3H), 
4.06 (ddd, J = 13.7, 7.0, 4.1 Hz, 1H), 3.57 – 3.44 (m, 2H), 3.31 (s, 3H), 3.08 (m, 2H), 2.87 
(s, 3H), 1.38 (t, J = 6.2 Hz, 3H), 1.27 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
163.33, 158.78, 147.22, 139.29, 138.35, 128.97, 128.57, 128.47, 127.26, 126.88, 126.12, 
115.37, 82.06, 61.45, 57.24, 47.06, 39.28, 36.93, 22.18, 15.68, 14.55. MS (ESI): calcd. 
490.22; found 490.33 [M+H]+.
4-(((S)-2-Methoxy-2-phenylethyl)amino)-5-methyl-2-((R)-2-phenylpropyl)thieno[2,3-
d]pyrimidine-6-carboxylic acid (54)
Isolated 42 mg (74% yield) as a yellow solid. 1H NMR (500 MHz, DMSO) δ 7.41 – 7.36 
(m, 2H), 7.34 – 7.29 (m, 3H), 7.26 – 7.19 (m, 4H), 7.12 – 7.08 (m, 1H), 7.00 (br. t, J = 5.5 
Hz, NH), 4.54 (dd, J = 7.6, 5.1 Hz, 1H), 3.76 – 3.70 (m, 1H), 3.69 – 3.62 (m, 1H), 3.18 (s, 
3H), 2.96 (m, 3H), 2.75 (s, 3H), 1.20 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
167.12, 165.02, 159.09, 147.68, 140.96, 139.62, 129.62, 129.43, 129.04, 127.96, 127.75, 
127.10, 122.45, 115.91, 82.02, 68.17, 57.70, 47.71, 39.55, 23.20, 16.25. HRMS (ESI): calcd. 
462.18514 for C26H28N3O3S; found 462.1847 [M+H]+.
Ethyl (S)-2-(4-acetamidophenethyl)-4-((2-methoxy-2-phenylethyl)amino)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylate 55 (precursor)
Isolated 40 mg (82% yield, over two steps) as a white powder. 1H NMR (300 MHz, CDCl3) 
δ 7.55 (s, 1H), 7.41 (m, 7H), 7.15 (d, J = 8.4 Hz, 2H), 6.16 (br. m, NH), 4.43 (dd, J = 8.6, 
3.8 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 4.14 (ddd, J = 14.0, 7.0, 4.3 Hz, 1H), 3.54 (ddd, J = 
13.7, 8.7, 3.8 Hz, 1H), 3.31 (s, 3H), 3.07 (m, 4H), 2.88 (s, 3H), 2.12 (s, 3H), 1.38 (t, J = 7.1 
Hz, 4H). 13C NMR (75 MHz, CDCl3) δ 163.32, 158.91, 150.73, 137.95, 129.11, 128.98, 
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126.87, 120.18, 115.46, 84.48, 61.49, 57.24, 47.08, 41.08, 33.87, 24.72, 15.72, 14.55. MS 
(ESI): calcd. 533.22; found 533.27[M+H]+.
(S)-2-(4-Acetamidophenethyl)-4-((2-methoxy-2-phenylethyl)amino)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylic acid (55)
Isolated 24 mg (63% yield) as a white powder. 1H NMR (500 MHz, DMSO) δ 9.81 (s, 
NHAc), 7.43 (d, J = 8.5 Hz, 2H), 7.39 – 7.28 (m, 5H), 7.12 (d, J = 8.5 Hz, 2H), 6.98 (br. t, J 
= 5.2 Hz, NH), 4.54 (dd, J = 7.7, 5.0 Hz, 1H), 3.80 (m, 1H), 3.67 (m, 1H), 3.18 (s, 3H), 2.98 
(m, 4H), 2.79 (s, 3H), 1.98 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.15, 167.82, 165.09, 
159.21, 141.02, 139.66, 138.37, 137.11, 129.61, 129.55, 129.00, 127.75, 122.32, 120.10, 
115.96, 82.14, 57.69, 47.66, 41.28, 33.91, 25.08, 16.33. HRMS (ESI): calcd. 505.19095 for 
C27H29N4O4S; found 505.1916 [M+H]+.
Protein expression and purification
The heterologous expression of PglD was accomplished using the E. coli BL-21(DE3) strain 
(Stratagene). Cells were transformed with pETNO-construct plasmids and grown to an A600 
of 0.6 absorbance units at 37 °C in Lysogeny broth; the cultures were cooled to 16 °C and 
then induced by the addition of 0.5 mM isopropyl-D-thiogalactopyranoside (IPTG). The 
pETNO plasmid is based on the pET30a plasmid modified to include a His8TEV 
(purification tag/protease cleavage site) in place of the existing His6-thrombin site. Twenty 
hours after induction the cells were harvested by centrifugation and resuspended in ice-cold 
buffer composed of 50 mM HEPES pH 7.1, 10 mM imidazole, 150 mM NaCl, at1/20 the 
original culture volume. Maintaining a working temperature of 4 °C, the cells were lysed by 
sonication, and the lysate was cleared by centrifugation in a Type 45 Ti rotor (Beckman/
Coulter) at 35,000 rpm. The extract was bound to Ni-NTA (Qiagen) in batch mode using 1 
mL of resin per liter of culture for 1h with gentle tumbling. The protein-bound resin was 
washed with 25 column volumes of lysis buffer containing 50 mM imidazole, and the 
protein was eluted in lysis buffer containing 250 mM imidazole. The hexahistidine tag was 
removed by TEV cleavage, and after the digest reached completion, the reaction was 
dialyzed twice against 4 L 20 mM HEPES pH 7.1, 150 mM NaCl with a 10,000 MWCO 
Snakeskin (Thermo Scientific). Further purification was performed by size exclusion 
chromatography using a Superdex 200 XK16–60 column (GE Healthcare) in a running 
buffer of 20 mM HEPES pH 7.1, 100 mM NaCl.
High-throughput screening – Broad Institute MLPCN
To a Nunc 384-well black-clear bottom plate (Thermo Scientific) was added 200 nL of 
compound in neat DMSO (final assay concentration = 10 μM) and 20 μL of enzyme solution 
(final assay concentrations: 6 nM PglD, 50 mM HEPES pH 7.4, 0.001% Triton, 0.05% BSA, 
100 μM AcCoA). Solution dispensing was accomplished utilizing a Multidrop Combi 
(Thermo Scientific). This mixture was allowed to incubate at room temperature for a 
duration of 45 minutes. The reaction was started by the addition of 10 μL reaction solution 
(final assay concentrations: 50 mM HEPES pH7.4, 100 μM UDP-4-aminosugar). The 
reaction was quenched after 30 minutes with the addition of 30 μL stop solution (final assay 
concentrations: 2 mM DTNB, 1 mM EDTA, 20% 1-propanol). The plates were allowed to 
develop for 5 minutes before reading at a λ = 405 nm.
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Enzymatic inhibition assay
Kinetic characterization of PglD inhibition was carried out by monitoring CoASH release 
resulting from the acetyltransferase reaction with Ellman’s reagent (DTNB) in a continuous 
fashion. To a flat, clear bottom 96-well plate (Falcon) was added sequentially the inhibitor as 
a DMSO stock solution, followed by PglD in 50 mM HEPES pH 7.8, 1 mM MgCl2, 0.05 
mg/mL BSA, 0.001% Triton X-100. Inhibitors and enzyme were pre-incubated 30 min at 
RT, followed by addition of substrate and Ellman’s reagent cocktail to final concentrations 
of 3 nM PglD, 500 μM 4-amino-sugar, 300 μM AcCoA, 2 mM DTNB and 3% DMSO in 
150 μL volume. Initial rates were measured in the linear portion of the reaction curve over a 
5 min time period at RT, measuring absorbance at 412 nm on a Synergy H1 hybrid plate 
reader from Biotek.
Dynamic Light Scattering
Samples were prepared in buffer 50 mM HEPES 7.5, 100 mM NaCl and a final 
concentration of 3% DMSO; the concentration of C jejuni PglD was 25 μM with or without 
250 μM inhibitor 57. DLS data was acquired on a Wyatt DynaPro Nanostar Light Scatterer 
by measuring scattering at a 90° angle with a 685 nm laser and analyzed with a Rayleigh 
scattering model using the Dynamics 7.1.9 software package.
Differential Scanning Fluorimetry
Samples were prepared to a final volume of 25 μL containing 10 μM PglD protein and 100 
μM inhibitor in a buffer containing 50 mM HEPES 7.5, 150 mM NaCl, 0.001 % Triton 
X-100, 10× Sypro orange (diluted from a commercial stock solution of 5000X; Invitrogen) 
and a final concentration of 3% DMSO. All samples were prepared in duplicate. 
Fluorescence was measured using a Roche Lightcycler 480 RT-PCR instrument while 
increasing the temperature gradient from 30 to 95°C in increments of 4.4°C/60 s. The 
midpoint temperature of the unfolding protein transition (Tm) was calculated using the built-
in functionality of the instrument software package.
Crystallization of C. jejuni PglD in complex with inhibitor 17
Initial crystallization screening was performed by sitting drop vapor diffusion using intelli-
plate® from Hampton Research with 50 μL/well solution, which was dispensed as a 0.15 μL 
drop followed 0.15 μL of 10 mg/mL PglD solution in SEC buffer. Screens used were PEG 
suite 1, PEG suite 2, PACT and ProComp from Qiagen, and drops were set up using an Art 
Robbins Phoenix robot. Diffraction quality crystals were formed via hanging drop vapor 
diffusion by mixing 1.5 μL of protein solution with 1.5 μL of reservoir solution (15% 
PEG-3350, 0.1M NaF and 10% glycerol) and incubation at 22 °C.
Ligand soaking: Wells were carefully opened and 50 μL of DMSO was added directly to the 
well; 0.75 μL of a solution containing 10 mM inhibitor 17 in reservoir solution (final 
concentration of 10% DMSO) was added directly to the drops on the slide. The crystals 
were then incubated for 30 min to 3 days, and then looped and flash frozen in liquid nitrogen 
without the need of separate cryoprotection.
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Data Collection, Processing, and Structure Refinement
Diffraction data was collected either at a home source (Rigaku Saturn 944 with 
MicroMax-007 HF and VariMax HF generator) or at the Advanced Photon Source (APS) at 
Argonne National Laboratory (in Argonne, Illinois, USA) national synchrotron on the 
NECAT-24ID beamline. The diffraction data were indexed and scaled with either HKL2000. 
The initial structure model was built by applying molecular replacement methods with a 
ligand/solvent-omitted input model generated from the PDB model 3BSY. The initial models 
were further improved through iterative rounds of manual and automated refinement with 
COOT.56 The final structure has been deposited into the Protein Data Bank PDB ID 5T2Y. 
Data collection and refinement statistics are presented in in the supporting information Table 
S3
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AcCoA acetyl coenzyme A
BOP (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
diNAcBac 2,4-diacetamido-2,4,6-trideoxy-α-D-glucose
PyBOP (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
DSF Differential scanning fluorimetry
DLS dynamic light scattering
PLP Pyridoxal 5′-phosphate
STD saturation transfer difference
UndP undecaprenyl phosphate
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Figure 1. 
Schematic representation of the C. jejuni N-linked protein glycosylation pathway. Enzymes 
are shown in italics with the oligosaccharyl transferase PglB shown as determined in PDB 
3RCE. Also shown is an N-linked glycosylation substrate PEB3 (PDB: 2HXW), which is a 
virulence factor in periplasm that is modified by N-linked glycosylation. Inset highlights the 
three sugar-modifying enzymes that convert UDP-GlcNAc to UDP-diNAcBac.
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Figure 2. 
Structure analysis of C. jejuni PglD. (a) Crystal structure of the PglD homotrimer (PDB 
3BSY) in cartoon representation; individual protomers are colored in green, blue and orange. 
(b) Expanded of view of the PglD active site protein surface with the AcCoA substrate 
shown in stick representation (magenta, PDB 3BSY) as well as the UDP-4-amino-sugar 
substrate (yellow, PDB 3BSS). (c) Crystal structure of fragment 1 (magenta) bound to PglD 
with a semi-transparent surface and selected side-chain residues shown in stick 
representation and annotated (PDB 5TYH). (d) Docking output pose generated for 
compound 3 (Glide, Maestro).38
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Figure 3. 
Representative examples of thienopyrimidine-6-carboxylate inhibitors of C. jejuni PglD; 
Core 11: R2 = a – z; R4 = a – z; Core 16: R2 = d, h; R4 = a.
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Figure 4. 
(a) Illustration of the quasi C2 symmetry axis of the disubstituted inhibitors (b) SAR of 
inhibitors 51 – 54 with rigidified R2 and R4 substituents; magenta symbols represent 
stereochemical preference of R2 and R4 substituents with respect to the PglD protein surface 
and highlight the mismatched/matched pattern.
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Figure 5. 
Structures of key inhibitors discussed in this section: 17, 43 and 55.
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Figure 6. 
Correlation between the in vitro potency against PglD and the Tm (calculated from the first 
derivative of the thermal melting curve) of the PglD/inhibitor complexes with core 11; 
thermal melt assays were performed with 10 μM PglD and 100 μM compound. Correlation 
coefficient provided for all data indicated by red diamond. Inhibitors with R4 = b 
(ethylamine) (blue diamond, circled) appear as outliers and are omitted from the calculation 
of the correlation coefficient.
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Figure 7. 
Co-crystal structure of the PglD/17 complex (PDB 5T2Y). (a) Inhibitor 17 shown in sticks 
presentation (magenta) and overlayed with AcCoA substrate in lines (cyan, PDB 3BSY) and 
sugar substrate in sticks (yellow, PDB 3BSS). (b) overlay with the computational docking 
pose of compound 2 in line representation (orange). (c) Side-view highlighting the AcCoA 
adenine sub-pocket and interaction between 17 and residues Gly173, Ile155 and Ser136. 
White dashed lines indicate distances between 17 and PglD side-chain residues; yellow 
dashed line shows distance between the carboxylate computational docking pose and crystal 
structure. (d) Composite omit map 2Fo –Fc contoured at 1.0 σ generated with the built in 
functionality of the PHENIX software and image generated in PYMOL.
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Scheme 1. 
General structure and numbering system of the thienopyrimidine core.
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Scheme 2. 
Synthesis of inhibitors with thienopyrimidine-6-carboxylate core 11
Conditions: (a) 1.2 equiv. R2CN, 4 M HCl in 1,4-dioxane, 90°C (50–90%); (b) 1.5 equiv. 
R4NH2, 1.3 equiv. PyBOP, 3 equiv. DBU, MeCN, RT (40–90%); (c) 1.2 equiv. ClCH2CN, 4 
M HCl in 1,4-dioxane, 90°C (50–90%) (d) 20 equiv. P(OEt)3, 145°C (85%); (e) 1.5 equiv. 
NaH, 2 equiv. ArCHO, THF, RT (70–90%); (f) 10% Pd(OH)2/C, THF/MeOH 1:1, 60°C 
(quant.); (g) 1.5 equiv. R4NH2, 1.3 equiv. PyBOP, 3 equiv. DBU, MeCN, RT (40–90%) (h) 3 
equiv. NaOH, THF/MeOH/H2O 2:1:1, RT (50–80%).
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Scheme 3. 
Synthesis of inhibitors with thienopyrimidine-6-carboxylate core 16
Conditions: (a) 4 equiv. SOCl2, MeOH, 50°C (99%); (b) 2 equiv. HNO3, H2SO4, RT; (c) 
10% Pd(OH)2/C, THF/MeOH 1:1, RT (93% over 2 steps); (d) 1.2 equiv. R2CN, 4 M HCl in 
1,4-dioxane, 90°C (60–80%); (e) 1.5 equiv. R4NH2, 1.3 equiv. PyBOP, 3 equiv. DBU, 
MeCN, RT (40–90%); (f) 3 equiv. NaOH in THF/MeOH/H2O 2:1:1, RT (50–80%).
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